



CURRICULUM VITAE

Jason Westin M.D., M.S., FACP

PRESENT TITLE AND AFFILIATION

Primary Appointment

Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

N/A

CITIZENSHIP

United States

OFFICE ADDRESS

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd
Unit Number: 429
Houston, TX 77030
Room Number: FC6.3060
Phone: (713) 792-3750
Fax: 713-794-5656
Email: jwestin@mdanderson.org

EDUCATION

Degree-Granting Education

University of Florida, Gainesville, FL, BS, Cum Laude, 1998, Microbiology

University of Florida, Gainesville, FL, MD, elected to AOA, 2002, Medicine

University of Texas Graduate School of Biomedical Sciences, Houston, TX, MS, 2015, Clinical and Translational Sciences

Postgraduate Training

Clinical Residency, University of North Carolina, Chapel Hill, NC, 6/2002-5/2005

Clinical Fellowship, Hematology/Oncology, M.D. Anderson Cancer Center, Houston, TX, 7/2008-6/2011

Chief Fellow, M.D. Anderson Cancer Center, Houston, TX, 7/2010-6/2011

Research Fellowship, Advanced Scholar - Lymphoma, University of Texas MD Anderson Cancer Center, Houston, TX, 6/2011-6/2012

CREDENTIALS

Board Certification

ABIM Internal Medicine, 8/2005-8/2015

ABIM Medical Oncology, 11/2021-4/2024

Licensures

Active

Texas, TX, M4650, 8/2006-8/2023

Florida, FL, TPME1658, 5/2021-8/2024

Inactive

North Carolina, NC, 2005-00505, 4/2005-8/2007

EXPERIENCE/SERVICE

Academic Appointments

Assistant Professor, Division of Internal Medicine, The University of North Carolina, Chapel Hill, NC, 6/2005-9/2006

Instructor, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2006-6/2008

Instructor, Department of Lymphoma/Myeloma - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2011-6/2012

Assistant Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 6/2012-8/2019

Associate Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2019-8/2023

Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2023-present

Administrative Appointments/Responsibilities

Director, Department of Lymphoma/Myeloma, Division of Cancer Medicine, Lymphoma Planning Clinic, Houston, TX, 8/2013-present

Hematology Grand Rounds, Lymphoma Chair, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/2013-10/2017

Clinical Operations Team Member, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2015-9/2018

Leader, DLBCL Clinical Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 11/2015-10/2019

EHR Officer, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 6/2018-6/2019

Member, American Society of Clinical Oncology Government Relations Committee, Alexandria, VA, 6/2019-present

Section Chief, Aggressive Lymphoma, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/2019-present

Director, Lymphoma Clinical Research, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 12/2019-present

Chair Elect, American Society of Clinical Oncology Government Relations Committee, Alexandria, VA, 6/2021-6/2022

Chair, American Society of Clinical Oncology Association Board's Finance Committee, Alexandria, VA, 6/2022-6/2023

Association Treasurer, American Society of Clinical Oncology Association Board of Directors, Alexandria, VA, 6/2022-6/2023

Board Member, American Society of Clinical Oncology Association Executive and Audit Committee, Alexandria, VA, 6/2022-present

Past Chair, American Society of Clinical Oncology Government Relations Committee, Alexandria, VA, 6/2023-6/2024

Other Appointments/Responsibilities

Chair, Diffuse Large B Cell Lymphoma Translational Biology Program, Houston, TX, 5/2013-present

ASCO PAC Advisory Council, American Society of Clinical Oncology Government Relations Committee, Alexandria, VA, 3/2023-present

Endowed Positions

N/A

Consultantships

N/A

Military or Other Governmental Service

N/A

Institutional Committee Activities

Clinical Research Committee, Member, 9/2007-8/2020

Steering Committee for MS/PhD in Clinical and Translational Sciences, University of Texas Graduate School of Biomedical Sciences, Member, 1/2010-1/2012

Steering Committee for University of Texas M.D. Anderson Hematology Oncology Fellowship Program, Member, 7/2010-7/2011

DLBCL Clinical Trial Team, MD Anderson Cancer Center Lymphoma Department, Member, 7/2010-present

New Drug Development Team, MD Anderson Cancer Center Lymphoma Department, Member, 1/2013-present

Lymphoma Informatics Committee, Chair, 4/2013-4/2015

eResearch Design Project Implementation Team, Faculty Lead, 9/2013-10/2013

MD Anderson Faculty Senate, Senator, 9/2013-9/2018

Institutional Review Board 2, Associate Member, 9/2019-8/2020

Scientific Review Committee #4, Advisory Member, 9/2020-8/2021

Advisory Clinical Research Council (ACRC), Advisory Member, 12/2020-present

Scientific Review Committee #4, Member, 9/2022-present

HONORS AND AWARDS

Alpha Omega Alpha Medical Honor Society, 2002

Equal Access Homeless Clinic Award, University of Florida College of Medicine, 2002

Intern of the Year Award, 2003

American Society of Hematology Travel Award, 2009

Janice Davis Singletary Fellowship for Lymphoma, M.D. Anderson Cancer Center, 2010

Paul Calabresi Career Development Award in Clinical Oncology, M.D. Anderson Cancer Center, 2010-2012

Clinical Research Training Institute, American Society of Hematology, 2011

Oncology Trainee Travel Award, ASCO Conquer Cancer Foundation, 2011

Young Investigator Award, ASCO Conquer Cancer Foundation, 2012-2013

R. Lee Clark Fellow, MD Anderson Cancer Center, 2014

Career Development Award, ASCO Conquer Cancer Foundation, 2015-2018

Lymphoma Clinical Research Mentoring Program, Lymphoma Research Foundation, 2015

Waun Ki Hong Award for Team Science, MD Anderson, 2016

Leadership Development Program, American Society of Clinical Oncology, 2019-2020

RESEARCH

Grants and Contracts

Funded

N/A

Pending

N/A

Other

N/A

Completed

Co-Principal Investigator, 75%, Paul Calabresi K12 Career Development Award in Clinical Oncology, 2 K12 CA088084 11(PP-6), NIH/NCI, 9/20/2010-9/19/2013 (\$102,416/year)

Co-Principal Investigator, 10%, Developing Combination Chemotherapy and Targeting Resistance in B-Cell Lymphoma, SDA 2011-12 RFA 20110506, Southwest Oncology Group, PI - R. Eric Davis, 8/15/2011-4/2014 (\$125,000/year)

Principal Investigator, ASCO YIA Targeting Chemotherapy Resistance in Diffuse Large B-Cell Lymphoma: Defining the Role of the PI3K/Akt/mTOR Pathway, American Society of Clinical Oncology (ASCO), 7/1/2012-12/2013 (\$50,000/year)

Principal Investigator, 5%, R. Lee Clark Fellow Award Development of Therapeutically Relevant Biomarkers in Relapsed Diffuse Large B Cell Lymphoma, MD Anderson Cancer Center, 4/2014-present (\$50,000/year)

Project Leader, 5%, B-Cell Lymphoma Moon Shot-Developing Minimal Residual Disease Assays, M.D. Anderson Cancer Center, 9/1/2014-present (\$70,000/year)

Project Leader, Conquer Foundation Career Development Award, American Society of Clinical Oncology (ASCO), PI - Jason Westin, M.D., 7/1/2015-6/30/2018, \$250,000

Co-Principal Investigator, Loan Repayment Clinical Research - Extramural, NIH/NCI

Not Funded

N/A

Protocols

Funded

Collaborator, A Phase II Randomized Study of Rituximab-HCVAD Alternating with Rituximab-Methotrexate-Cytarabine -vs- Standard Rituximab-CHOP Every 212 Days for Patients with Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger, 2005-0054, PI - Luis E. Fayad, M.D., 2005-2010, Genentech

Co-Principal Investigator, Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss in Lymphoma Patients Receiving Chemotherapy, 2005-0698, 2005-2011

Co-Principal Investigator, Phase II Safety and Efficacy Study of the Monoclonal Antibody CT-011 in, 2009-0163, 2009-2013

Principal Investigator, CTSU 9177/DA-EPOCH, 2009-0833, 2009-2018

Co-Principal Investigator, Phase 0 trial evaluating the effect of temsirolimus on known pharmacodynamic targets, 2010-0259, PI - Kurzrock, 2010-2016

Collaborator, A Multicenter, Open-Label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects with Relapsed or Refractory De Novo Diffuse Large B-Cell Lymphoma, 2011-0134, PI - Nathan Fowler, M.D., 2011-2014, Pharmacyclics

Collaborator, A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination with Bendamustine/Rituximab (BR) in Subjects with Relapsed or Refractory Non-Hodgkin's Lymphoma, 2011-1233, PI - Loretta Nastoupil, M.D., 2011-2015, Abbott

Collaborator, A Phase 2/3 Multicenter, Randomized Open-Label Study to Compare the Efficacy and Safety of Lenalidomide (Revlimid) Versus Investigator's Choice in Patients with

Relapsed or Refractory Diffuse Large B-cell Lymphoma, 2010-0272, PI - Yasuhiro Oki, M.D., 2011-2016, Celgene

Study Chairman, A Retrospective Evaluation of Patients Treated at M.D. Anderson Cancer Center for Mediastinal Lymphoma, DR11-0096, 2011-2016, Amgen

Collaborator, An Extension Study to Investigate the Safety and Durability of Clinical Activity of CAL-101 in Patients with Hematologic Malignancies, 2011-1182, PI - Nathan Fowler, M.D., 2011-2016, Calistoga Pharmaceuticals, Inc.

Collaborator, A Phase 1b Study Combining Ibrutinib with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects with CD20-Positive B-Cell Non-Hodgkin Lymphoma (NHL), 2012-0293, PI - Yasuhiro Oki, M.D., 2012-2014, Janssen Research & Development, LLC

Principal Investigator, A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (ibritumomab tiuxetan) versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy, 2012-0504, 2012-2014, Spectrum

Co-Principal Investigator, A Phase I/II Study of Carfilzomib plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory B-Cell Non-Hodgkins Lymphoma, 2012-0188, PI - Michael Wang, M.D., 2012-2014, M.D. Anderson Cancer Center

Principal Investigator, An Open Label Phase II Study of BKM120 in Patients with Relapsed and Refractory DBLCL, MCL and FL, 2012-0696, 2012-2014, Novartis

Principal Investigator, Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients with Relapse or Refractory Diffuse Large B Cell Lymphoma, 2012-0226, 2012-2014, Rigol

Co-Investigator, A Phase 2 Study of Brentuximab Vedotin in Combination with Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) as Front-Line Therapy in Patients with Diffuse Large B-Cell Lymphoma (DLBCL), 2013-0564, PI - Luis Fayad, M.D., 2013-2016, Seattle Genetics

Study Chairman, A Retrospective Evaluation of Patients Treated at M.D. Anderson Cancer Center for Relapsed Diffuse Large B-cell Lymphoma, PA13-0046, 2013-2016

Co-Principal Investigator, Rituximab and Statins: A Review of M.D. Anderson Protocols Involving Rituximab to Determine if Statins Have an Adverse Influence on Outcomes, DR09-0500, PI - Dr. Peter W. McLaughlin, 2013-2017

Collaborator, A Phase I/II Study of Lenalidomide and Obinutuzumab (GA101) in Relapsed Indolent Non-Hodgkin's Lymphoma, 2013-0261, PI - Nathan Fowler, M.D., 2013-present, Celgene, Genentech

Collaborator, A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects with Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma, 2013-0425, PI - Yasuhiro Oki, M.D., 2013-present, Janssen Research & Development, LLC

Study Chairman, A Retrospective Review of Therapeutic Outcomes with Diffuse Large B-Cell Lymphoma Therapy at M.D. Anderson Cancer Center, PA13-0374, 2013-present

Principal Investigator, Phase II Clinical Trial with the Novel MEK Inhibitor AZD-6244, 2013-0366, 2013-present, CTEP

Co-Investigator, Phase III, Multicenter, Open-Label, Randomized Trial Comparing the Efficacy of GA101 (RO5072759) in Combination with CHOP (G-CHOP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL), 2012-1155, PI - Luis Fayad, M.D., 2013-present, Genentech

Collaborator, The Outcome of Patients With Primary Mediastinal B-Cell Lymphoma Treated With and Without Radiation Therapy, PA13-0112, PI - Chelsea Pinnix, 2013-present

Principal Investigator, A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), 2014-0703, 2014-2017, Karyopharm

Principal Investigator, Phase II study of MLN0128 in relapsed lymphoma, 2014-0501, 2014-2017, Millennium

Principal Investigator, Phase II study of PNT2258 in Patients with Heavily Pretreated DLBCL, 2014-0667, 2014-2017, ProNai Therapeutics

Co-Investigator, A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-LAG-3 (BMS-986016) in Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas, 2014-0018, PI - Sattva Neelapu, M.D., 2014-present, Bristol-Myers Squibb

Co-Investigator, A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL), 2014-0815, PI - Sattva Neelapu, M.D., 2014-present, Kite Pharma, Inc.

Collaborator, A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced/Metastatic Solid Tumors and B-Cell Non-Hodgkins Lymphoma, 2014-0651, PI - Erminia Massarelli, M.D., 2014-present, Bristol-Myers Squibb

Co-Investigator, A Phase 1b, Multi-center, Open-label Study of 2 Dosing Regimens of ACP-196 in Subjects with Relapsed or Refractory De Novo Activated B-Cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma, 2014-0337, PI - Nathan Fowler, M.D., 2014-present, Acerta Pharma, Inc.

Co-Principal Investigator, Evaluation of Salvage Radiation Therapy Prior to Autologous Stem Cell Transplant in Patients with Chemorefractory B-Cell Lymphoma, PA14-0973, PI - Chelsea Pinnix, M.D., 2014-present

Collaborator, Phase 1/2 Open-label, Multiple-dose, Dose-escalation Study to Evaluate the Safety and Tolerability of IMO-8400 in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma and MyD88 L265P Mutation, 2014-0705, PI - Yasuhiro Oki, M.D., 2014-present, Idera Pharmaceuticals

Principal Investigator, A Phase III Study of Lenalidomide and Obinutuzumab with CHOP for Diffuse Large B-Cell Lymphoma, 2015-0069, 2015-2017, Genentech

Principal Investigator, An International, Phase II, Open-Label, Efficacy and Safety study of MDV9300 in Patients with an Incomplete Response Following Salvage Therapy or Autologous Stem Cell Transplantation for Relapsed or Refractory CD20+ Diffuse Large B-Cell Lymphoma, 2015-0590, 2015-2017

Principal Investigator, A Phase I/II Study of Lenalidomide and Obinutuzumab with CHOP for Diffuse Large B Cell Lymphoma, 2015-0069, 2015-2018, Celgene / Genentech

Principal Investigator, Randomized Placebo-Controlled Study of Loritadine for Pegfilgrastim Induced Bone Pain in Patients with Aggressive Lymphoma (Loritadine), 2014-0880, 2015-2018, Amgen

Principal Investigator, A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced/Metastatic Solid Tumors and B Cell with Non-Hodgkins Lymphoma, 2014-0651, 2015-present, BMS

Principal Investigator, DNA Sequencing Based monitoring MRD, PA15-0957, 2015-present

Principal Investigator, LTFU Car-T, 2015-0569, 2015-present, Novartis

Principal Investigator, Pilot Project for Creation of the DLBCL Response Prediction Model: Combining Early Interim Functional Imaging with Detection of a Tumor-Specific Clonotype in

Blood of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma to Predict Response to Standard Immunochemotherapy, 2015-0022, 2015-present, Sequentia

Principal Investigator, A Phase II Study of Pembrolizumab (MK-3475) in Subjects with Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL), 2015-0916, PI - Jason R Westin, 2016-2018

Principal Investigator, Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL), 2015-0567, 2016-2018, Novartis

Principal Investigator, A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib Combined with Dose Adjusted Chemotherapy for Patients with High Risk Diffuse Large B-Cell Lymphoma (SMART Start), 2015-0147, 2016-present, Janssen/Celgene

Study Chairman, Blood to detect circulating tumor genetics, PA16-0101, 2016-present

Principal Investigator, E7438, 2016-0438, 2016-present

Principal Investigator, Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Combination with Atezolizumab in Subjects with Refractory Diffuse Large B-Cell Lymphoma (DLBCL), 2016-0574, 2016-present, Kite

Principal Investigator, Atezolizumab w/Obinotuzumab and /or Tazemetostat, 2017-0195, 2017-2018

Principal Investigator, Venetoclax + DA-EPOCH-R, 2017-0025, 2017-2018

Principal Investigator, ZUMA-7, 2017-0699, 2017-present

Principal Investigator, LONG-TERM FOLLOW-UP STUDY OF SUBJECTS TREATED WITH AN AUTOLOGOUS T CELL PRODUCT EXPRESSING AN ANTIBODY COUPLED T CELL RECEPTOR (ACTR), 2018-0815, 2018-2019, Cogent Biosciences

Principal Investigator, A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkins Lymphoma, 2018-0999, 2018-2021, Gilead

Principal Investigator, ACTR707, an Autologous T Cell product, in combination with Rituximab, 2018-0373, 2018-present

Principal Investigator, Nivolumab & Ibrutinib for Relapsed CNS, 2018-0510, 2018-present

Principal Investigator, A Phase Ib, open-label, randomized study to assess safety and preliminary efficacy of Tafasitamab in addition to R-CHOP or Tafasitamab plus Lenalidomide in addition to R-CHOP in patients with newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) – First-MIND, 2019-1249, 2019, Incyte / Morphosys

Principal Investigator, Phase 1/2 Open-Label, Multi-center, Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered Fimepinostat (CUDC-907), a PI3K and HDAC Inhibitor, in Subjects with Relapsed and/or Refractory Lymphoma, 2019-0184, 2019-2020, Curis

Principal Investigator, 2021-0370, A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-, 2021-present, Incyte / Morphosys

Principal Investigator, A Phase 1b, open label, global, multicenter, dose determination, randomized dose expansion study to determine the maximum tolerated dose, assess the safety and tolerability, pharmacokinetics and preliminary efficacy of iberdomide (CC-220) in combination with R- CHOP-21 and CC-99282 in combination with R-CHOP-21 for subjects with previously untreated, poor risk (IPI 3 to 5), aggressive B-cell lymphoma, 2021-0369, 2021-present, BMS

Principal Investigator, Smart Stop: A Phase II trial of Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab prior to and with standard chemotherapy for patients with newly diagnosed DLBCL, 2021-0046, 2021-present, Incyte / AstraZeneca / BMS

Unfunded

N/A

Patents and Technology Licenses

Patents

N/A

Technology Licenses

N/A

Grant Reviewer/Service on Study Sections

N/A

PUBLICATIONS

Peer-Reviewed Original Research Articles

1. Westin JR, Fayad LE. Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratification. *Curr Hematol Malig Rep* 4(4):218-24, 10/2009. PMID: 20425411.
2. Westin J, McLaughlin P. De novo CD5+ diffuse large B-cell lymphoma: a distinct subset with adverse features, poor failure-free survival and outcome with conventional therapy. *Leuk Lymphoma* 51(1):161-3, 1/2010. PMID: 19863175.
3. Davis RE, Westin JR. Vive la resistance: stem cells in mantle cell lymphoma. *Leuk Lymphoma* 52(6):944-5, 6/2011. e-Pub 4/2011. PMID: 21463111.
4. Westin JR, Saliba RM, De Lima M, Alousi A, Hosing C, Qazilbash MH, Khouri IF, Shpall EJ, Anderlini P, Rondon G, Andersson BS, Champlin R, Couriel DR. Steroid-Refractory Acute GVHD: Predictors and Outcomes. *Adv Hematol* 2011:601953, 2011. e-Pub 11/2011. PMCID: PMC3216266.
5. Westin JR, Kurzrock R. It's About Time: Lessons for Solid Tumors from Chronic Myelogenous Leukemia Therapy. *Mol Cancer Ther* 11(12):2549-55, 12/2012. e-Pub 11/2012. PMID: 23204432.
6. Westin JR, Gibbs A, Mills KR, Neelapu SS. Hodgkin lymphoma untreated for six years presenting with tracheoesophageal fistula. *Case Report Med* 2012:457908, 2012. e-Pub 7/2012. PMCID: PMC3395413.
7. Westin JR, Neelapu SS. Therapy of newly diagnosed follicular lymphoma. *Front Oncol* 2:188, 2012. e-Pub 12/2012. PMID: 23248775.
8. Westin JR, Thompson MA, Cataldo VD, Fayad LE, Fowler N, Fanale MA, Neelapu S, Samaniego F, Romaguera J, Shah J, McLaughlin P, Pro B, Kwak LW, Sanjorjo P, Murphy WA, Jimenez C, Toth B, Dong W, Hagemester FB. Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial. *Clin Lymphoma Myeloma Leuk* 13(2):99-105, 4/2013. e-Pub 12/2012. PMCID: PMC3881262.
9. Dabaja BS, Phan J, Mawlawi O, Medeiros LJ, Etzel C, Liang FW, Podaloff D, Oki Y, Hagemester FB, Chuang H, Fayad LE, Westin JR, Shihadeh F, Allen PK, Wogan CF, Rodriguez MA. Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma. *Leuk Lymphoma* 54(12):2631-8, 12/2013. e-Pub 5/2013. PMCID: PMC3827734.
10. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemester FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. *Br J Haematol* 163(5):611-20, 12/2013. e-Pub 10/2013. PMID: 24117234.

11. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. *Lancet Oncol* 15(1):69-77, 1/2014. e-Pub 12/2013. PMID: PMC3922714.
12. Cai Q, Westin J, Fu K, Desai M, Zhang L, Huang H, Jiang W, Liang R, Qian Z, Champlin RE, Wang M. Accelerated Therapeutic Progress in Diffuse Large B-cell Lymphoma. *Ann Hematol* 93(4):541-56, 4/2014. e-Pub 12/2013. PMID: 24375125.
13. Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J, Bandyopadhyay N, de Vries R, Balasubramanian S, Hellemans P, Smit JW, Fournau N, Oki Y. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naïve patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomized, phase 1b study. *Lancet Oncol* 15(9):1019-26, 8/2014. e-Pub 7/2014. PMID: 25042202.
14. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double Hit Lymphoma: the MD Anderson Cancer Center clinical experience. *Br J Haematol* 166(6):891-901, 9/2014. e-Pub 6/2014. PMID: 24943107.
15. Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L, Oki Y, Fanale M, Fowler N, Nastoupil L, Feng L, Loyer E, Younes A. Paclitaxel, toptotecan and rituximab: long term outcomes of an effective salvage programmed for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. *Br J Haematol* 167(2):177-84, 10/2014. e-Pub 7/2014. PMID: 25039868.
16. Westin JR. Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma. *Clin Lymphoma Myeloma Leuk* 14(5):335-342, 10/2014. e-Pub 2/2014. PMID: PMC4125533.
17. Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. *Lancet Oncol* 15(12):1311-8, 11/2014. e-Pub 10/2014. PMID: 25439689.
18. Cheah CY, Oki Y, Westin JR, Turturro F. A clinician's guide to double hit lymphomas. *Br J Haematol* 168(6):784-785. e-Pub 12/2014. PMID: 25529575.
19. Sasaki K, Pemmaraju N, Westin JR, Wang WL, Khoury JD, Podaloff DA, Moon B, Daver N, Borthakur G. A single case of rosai-dorfman disease marked by pathologic fractures, kidney failure, and liver cirrhosis treated with single-agent cladribine. *Front Oncol* 4:297, 2014. e-Pub 10/2014. PMID: PMC4212618.
20. Westin JR. Busting Robustness: Using Cancer's Greatest Strength to Our Advantage. *Future Oncology* 11(1):73-77, January 2015, 1/2015. PMID: 24673642.
21. Bui PL, Vicens RA, Westin JR, Jensen CT. Multimodality imaging of Epstein-Barr virus-associated inflammatory pseudotumor-like follicular dendritic cell tumor of the spleen: case report and literature review. *Clin Imaging*. e-Pub 1/2015. PMID: 25725946.
22. Tao R, Allen PK, Rodriguez A, Shihadeh F, Pinnix CC, Arzu I, Reed VK, Oki Y, Westin JR, Fayad LE, Medeiros LJ, Dabaja B. Benefit of Consolidative Radiation Therapy for Primary Bone Diffuse Large B-Cell Lymphoma. *Int J Radiat Oncol Biol Phys*. e-Pub 3/2015. PMID: 25754633.
23. Oki Y, Younes A, Knickerbocker J, Samaniego F, Nastoupil L, Hagemeister F, Romaguera J, Fowler N, Kwak L, Westin J. Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma. *Haematologica*. e-Pub 3/2015. PMID: 25820332.
24. Pinnix CC, Smith GL, Milgrom S, Osborne EM, Reddy JP, Akhtari M, Reed V, Arzu I, Allen PK, Wogan CF, Fanale MA, Oki Y, Turturro F, Romaguera J, Fayad L, Fowler N, Westin J, Nastoupil L, Hagemeister FB, Rodriguez MA, Ahmed S, Nieto Y, Dabaja B. Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiation Therapy for

- Hodgkin and Non-Hodgkin Lymphoma. *Int J Radiat Oncol Biol Phys* 92(1):175-182, 5/2015. PMID: 25863764.
25. Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, Rodriguez MA, Fayad L, Hagemeister FB, Nastoupil L, Turturro F, Fowler N, Fanale MA, Nieto Y, Khouri IF, Ahmed S, Medeiros LJ, Davis RE, Westin J. Single-Institution Experience in the Treatment of Primary Mediastinal B Cell Lymphoma Treated With Immunochemotherapy in the Setting of Response Assessment by (18)Fluorodeoxyglucose Positron Emission Tomography. *Int J Radiat Oncol Biol Phys* 92(1):113-121, 5/2015. PMID: 25863759.
26. Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, Fayad L, Samaniego F, Turturro F, Oki Y, Chen W, Badillo M, Nomie K, Rosa MD, Zhao D, Lam L, Addison A, Zhang H, Young KH, Li S, Santos D, Medeiros LJ, Champlin R, Romaguera J, Zhang L. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. *Lancet Oncol.* e-Pub 11/2015. PMID: 26640039.
27. Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, Voorhees P, Leleu X, Johnsen HE, Streetly M, Ludwig H, Mellqvist UH, Chng WJ, Pilarski L, Einsele H, Hou J, Turesson I, Zamagni E, Chim J, Mazumder A, Westin J, Lu J, Reiman T, Kristinsson S, Joshua D, Roussel M, O'Gorman P, Terpos E, Dimopoulos M, Moreau P, Anderson K, Palumbo A, Kumar S, Rajkumar V, Durie B, Richardson P. Management of relapsed multiple myeloma: Recommendations of the international myeloma working group. *Leukemia.* e-Pub 12/2015. PMID: 26710887.
28. Chihara D, Cheah CY, Westin JR, Fayad LE, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak LW, Wang ML, Romaguera JE. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. *Br J Haematol.* e-Pub 12/2015. PMID: 26648336.
29. Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, Hagemeister FB, Fayad LE, Westin JR, Oki Y, Fanale MA, Romaguera JE, Wang ML, Lee H, Turturro F, Samaniego F, Rodriguez MA, Neelapu SS, Fowler NH. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. *Ann Oncol.* e-Pub 1/2016. PMID: 26802151.
30. Pinnix CC, Shah JJ, Chuang H, Costelloe CM, Medeiros LJ, Wogan CF, Reed V, Smith GL, Milgrom S, Patel K, Huo J, Turturro F, Romaguera J, Fayad L, Oki Y, Fanale MA, Westin J, Nastoupil L, Hagemeister FB, Rodriguez A, Qazilbash M, Shah N, Bashir Q, Ahmed S, Nieto Y, Hosing C, Rohren E, Dabaja B. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. *Clin Lymphoma Myeloma Leuk* 16(3):122-8, 3/2016. e-Pub 12/2015. PMID: 26795083.
31. Cheah CY, Chihara D, Horowitz S, Sevin A, Oki Y, Zhou S, Fowler NH, Romaguera JE, Turturro F, Hagemeister FB, Fayad LE, Wang M, Neelapu SS, Nastoupil LJ, Westin JR, Rodriguez MA, Samaniego F, Anderlini P, Nieto Y, Fanale MA. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. *Ann Oncol.* e-Pub 4/2016. PMID: 27091808.
32. Pinnix CC, Osborne EM, Chihara D, Lai P, Zhou S, Ramirez MM, Oki Y, Hagemeister FB, Rodriguez AM, Samaniego F, Fowler N, Romaguera JE, Turturro F, Fayad L, Westin JR, Nastoupil L, Neelapu SS, Cheah CY, Dabaja BS, Milgrom SA, Smith GL, Horace P, Milbourne A, Wogan CF, Ballas L, Fanale MA. Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. *JAMA Oncol* 2(8):1065-9, 8/2016. e-Pub 5/2016. PMID: 27227654.
33. Issa AK, Westin JR. What to Do With Success? The Optimist's Creed in Relapsed Hodgkin Lymphoma. *Clin Lymphoma Myeloma Leuk* 16(9):483-487, 9/2016. e-Pub 6/2016. PMID: 27364263.
34. Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ. Management strategies and outcomes for very elderly patients

- with diffuse large B-cell lymphoma. *Cancer* 122(20):3145-3151, 10/2016. e-Pub 6/2016. PMID: 27351173.
35. Chen Y, Neelapu S, Feng L, Bi W, Yang TH, Wang M, Fanale MA, Westin JR, Hagemester FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Fowler NH, McLaughlin P, Cabanillas F, Oki Y, Nastoupil LJ, Rodriguez A. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β 2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. *Br J Haematol* 175(2):290-299, 10/2016. e-Pub 7/2016. PMID: 27448187.
 36. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemester FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Hosing C, Nieto YL, Oki Y. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. *Br J Haematol* 176(5):1365-2141, 3/2017. e-Pub 12/2016. PMID: 27983760.
 37. Nastoupil LJ, McLaughlin P, Feng L, Neelapu SS, Samaniego F, Hagemester FB, Ayala A, Romaguera JE, Goy AH, Neal E, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, Fowler NH. High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. *Br J Haematol* 177(2):263-270, 4/2017. e-Pub 3/2017. PMID: 28340281.
 38. Lee HJ, Romaguera JE, Feng L, Desai AP, Zhang L, Fanale M, Samaniego F, Hagemester FB, Fayad LE, Rodriguez MA, Medeiros JL, Hartig K, Nomie K, Ahmed M, Badillo M, Ye H, Oki Y, Lin P, Nastoupil L, Westin J, Wang M. Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. *Oncologist* 22(5):549-553, 5/2017. e-Pub 4/2017. PMCID: PMC5423503.
 39. Huang XJ, Liu K, Ritchie D, Andersson B, Lu J, Hou J, Burguera AF, Wang J, Yeoh A, Yan C, Zhou D, Tan D, Kim DW, Wu D, Shpall E, Kornblau S, Neelapu S, Hongeng S, Li J, Hu J, Zhang LS, Wang M, Malhotra P, Jiang Q, Qin Y, Wong R, Champlin R, Hagemester F, Westin J, Iyer S, Mathews V, Wang Y, Hu Y, Xiao Z, Shao Z, Orlowski RZ, Chim CS, Mulligan S, Sanz M, Ozawa K, Parmar S, Issaragrisil S. Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China. *Oncotarget* 8(25):41620-41630, 6/2017. e-Pub 2/2017. PMID: 28404929.
 40. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemester F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. *Head Neck* 39(6):1095-1100, 6/2017. e-Pub 4/2017. PMID: 28370694.
 41. Fanale MA, Cheah CY, Rich A, Medeiros LJ, Lai CM, Oki Y, Romaguera JE, Fayad LE, Hagemester FB, Samaniego F, Rodriguez MA, Neelapu SS, Lee HJ, Nastoupil L, Fowler NH, Turturro F, Westin JR, Wang ML, McLaughlin P, Pinnix CC, Milgrom SA, Dabaja B, Horowitz SB, Younes A. Encouraging activity for R-CHOP in Advanced Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma. *Blood* 130(4):472-477, 7/2017. e-Pub 5/2017. PMCID: PMC5578726.
 42. Fanale MA, Cheah C, Rich A, Medeiros LJ, Lai CM, Oki Y, Romaguera JE, Fayad LE, Hagemester F, Samaniego F, Rodriguez MA, Neelapu S, Lee HJ, Nastoupil L, Fowler N, Turturro F, Westin J, Wang M, McLaughlin P, Pinnix C, Milgrom S, Dabaja B, Horowitz S, Younes A. Potential Improvement of Clinical Outcomes for Advanced Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma Patients Treated With R-CHOP, 7/2017.
 43. Havranek O, Xu J, Köhrer S, Wang Z, Becker L, Comer JM, Henderson J, Ma W, Man Chun Ma J, Westin JR, Ghosh D, Shinnars N, Sun L, Yi AF, Karri AR, Burger JA, Zal T, Davis RE. Tonic B-cell receptor signaling in diffuse large B-cell lymphoma. *Blood* 130(8):995-1006, 8/2017. e-Pub 6/2017. PMID: 28646116.
 44. Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, Boussetta S, Feng L, Maurer MJ, Navale L, Wiezorek J, Go WY, Gisselbrecht C. Outcomes in refractory diffuse large B-cell lymphoma: results from the

- international SCHOLAR-1 study. *Blood* 130(16):1800-1808, 10/2017. e-Pub 8/2017. PMCID: PMC5649550.
45. Li X, Xu-Monette ZY, Yi S, Dabaja BS, Manyam GC, Westin J, Fowler N, Miranda RN, Zhang M, Ferry JA, Medeiros LJ, Harris NL, Young KH. Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrococytes in the Germinal Center. *Am J Surg Pathol* 41(10):1309-1321, 10/2017. PMID: 28817403.
 46. Chihara D, Westin JR, Miranda RN, Cheah CY, Oki Y, Turturro F, Romaguera JE, Neelapu SS, Nastoupil LJ, Fayad LE, Rodriguez MA, Fowler NH, Orlowski RZ, Wang M, Hagemeister FB, Medeiros LJ, Fanale MA. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. *Br J Haematol* 179(3):503-506, 11/2017. e-Pub 7/2016. PMID: 27378601.
 47. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycok J, Elias M, Chang D, Wiecek J, Go WY. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. *N Engl J Med* 377(26):2531-2544, 12/2017. e-Pub 12/2017. PMCID: PMC5882485.
 48. Chihara D, Fowler NH, Oki Y, Fanale MA, Fayad LE, Westin JR, Hagemeister FB. Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement. *Br J Haematol* 179(5):851-854, 12/2017. e-Pub 8/2016. PMID: 27502933.
 49. Quesada AE, Medeiros LJ, Desai PA, Lin P, Westin JR, Hawsawi HM, Wei P, Tang G, Seegmiller AC, Reddy NM, Yin CC, Wang W, Xu J, Miranda RN, Zuo Z, Li S. Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma. *Mod Pathol* 30(12):1688-1697, 12/2017. e-Pub 8/2017. PMID: 28776574.
 50. Ho JC, Dabaja BS, Milgrom SA, Smith GL, Reddy JP, Mazloom A, Young KH, Deng L, Medeiros LJ, Dong W, Allen PK, Andraos TY, Fowler NH, Nastoupil LJ, Oki Y, Fayad LE, Turturro F, Neelapu SS, Westin J, Hagemeister FB, Rodriguez MA, Pinnix CC. Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma(). *Leuk Lymphoma* 58(12):1-12, 12/2017. e-Pub 5/2017. PMID: 28482717.
 51. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Lohin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. *Nat Rev Clin Oncol* 15(1):47-62, 1/2018. e-Pub 9/2017. PMID: 28925994.
 52. Strati P, Fowler N, Pina-Oviedo S, Medeiros LJ, Overman MJ, Romaguera JE, Nastoupil L, Wang M, Hagemeister FB, Rodriguez A, Oki Y, Westin J, Turturro F, Neelapu SS, Fayad L. Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. *Clin Lymphoma Myeloma Leuk* 18(1):e103-e108, 1/2018. e-Pub 11/2017. PMID: 29196178.
 53. Liu W, Chen J, Tamayo AT, Ruan C, Li L, Zhou S, Shen C, Young KH, Westin J, Davis RE, Hu S, Medeiros LJ, Ford RJ, Pham LV. Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma. *Oncotarget* 9(1):346-360, 1/2018. e-Pub 8/2017. PMCID: PMC5787470.
 54. Hu B, Younes A, Westin JR, Turturro F, Claret L, Feng L, Fowler N, Neelapu S, Romaguera J, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Copeland AR, Nastoupil LJ, Nieto Y, Fanale MA, Oki Y. Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. *Leuk Lymphoma* 59(4):1-8, 4/2018. e-Pub 8/2017. PMID: 28792260.
 55. Milgrom SA, Pinnix CC, Chi TL, Vu TH, Gunther JR, Sheu T, Fowler N, Westin JR, Nastoupil LJ, Oki Y, Fayad LE, Neelapu S, Rodriguez MA, Hagemeister FB, Fanale MA, Lee HJ, Hosing C, Ahmed S, Nieto Y, Shpall EJ, Dabaja BS. Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. *Int J Radiat Oncol Biol Phys* 100(5):1146-1154, 4/2018. e-Pub 1/2018. PMID: 29452771.

56. Galanina N, Smith SM, Liao C, Petrich A, Libao B, Gartenhaus R, Westin JR, Cohen KS, Knost JA, Stadler WM, Doyle A, Karrison T, Gordon LI, Evens AM. University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL. *Br J Haematol* 181(2):264-267, 4/2018. e-Pub 4/2017. PMCID: PMC5785463.
57. Jain P, Romaguera J, Srour SA, Lee HJ, Hagemeister F, Westin J, Fayad L, Samaniego F, Badillo M, Zhang L, Nastoupil L, Kanagal-Shamanna R, Fowler N, Wang ML. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). *Br J Haematol*. e-Pub 5/2018. PMID: 29785709.
58. Chihara D, Fowler NH, Oki Y, Fanale MA, Nastoupil LJ, Westin JR, Fayad LE, Neelapu SS, Cheah CY. Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis. *Oncotarget* 9(48):28897-28902, 6/2018. e-Pub 6/2018. PMCID: PMC6034756.
59. Pinnix CC, Ng AK, Dabaja BS, Milgrom SA, Gunther JR, Fuller CD, Smith GL, Abou Yehia Z, Qiao W, Wogan CF, Akhtari M, Mawlawi O, Medeiros LJ, Chuang HH, Martin-Doyle W, Armand P, LaCasce AS, Oki Y, Fanale M, Westin J, Neelapu S, Nastoupil L. Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. *Blood Adv* 2(11):1334-1343, 6/2018. PMCID: PMC5998935.
60. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Ju Lee H, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. *Head Neck* 40(6):1335, 6/2018. e-Pub 2/2018. PMID: 29851218.
61. Pham LV, Huang S, Zhang H, Zhang J, Bell T, Zhou S, Pogue E, Ding Z, Lam L, Westin J, Davis RE, Young KH, Medeiros LJ, Ford RJ, Nomie K, Zhang L, Wang M. Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas. *Clin Cancer Res* 24(16):3967-3980, 8/2018. e-Pub 4/2018. PMID: 29666304.
62. Jain P, Kanagal-Shamanna R, San Lucas FA, Nastoupil L, Romaguera J, Fayad L, Oki Y, Westin JR, Medeiros LJ, Wang M, Fowler N. Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors. *Br J Haematol* 182(5):718-723, 9/2018. e-Pub 8/2017. PMCID: PMC5904008.
63. Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, Advani RH, Levy R, Newman AM, Dührsen U, Hüttmann A, Meignan M, Casasnovas RO, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA. Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. *J Clin Oncol* DOI: 10.1200/JCO.2018.78.5246(28):2845-2853, 10/2018. e-Pub 8/2018. PMCID: PMC6161832.
64. Ludmir EB, Milgrom SA, Pinnix CC, Gunther JR, Westin J, Oki Y, Fayad LE, Medeiros LJ, Dabaja BS, Nastoupil LJ. Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure. *Leuk Lymphoma* 59(12):1-8, 12/2018. e-Pub 4/2018. PMID: 29697005.
65. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Oki Y. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. *PLoS One* 13(3):e0191461, 2018. e-Pub 3/2018. PMCID: PMC5851529.
66. Yoder AK, Gunther JR, Milgrom SA, Mirkovic D, Nastoupil L, Neelapu S, Fanale M, Fowler N, Westin J, Lee HJ, Rodriguez MA, Iyer SP, Fayad L, Nieto YL, Hosing C, Ahmed S, Medeiros LJ, Khoury JD, Garg N, Amini B, Dabaja BS, Pinnix CC. Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. *Clin Lymphoma Myeloma Leuk* 19(1):e51-e61, 1/2019. e-Pub 9/2018. PMCID: PMC6371800.

67. Santomaso B, Bachier C, Westin J, Rezvani K, Shpall EJ. The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden. *Am Soc Clin Oncol Educ Book* 39:433-444, 1/2019. e-Pub 5/2019. PMID: 31099694.
68. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarsz RT, JULIET Investigators. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *N Engl J Med* 380(1):45-56, 1/2019. e-Pub 12/2018. PMID: 30501490.
69. Liang WS, Vergilio JA, Salhia B, Huang HJ, Oki Y, Garrido-Laguna I, Park H, Westin JR, Meric-Bernstam F, Fabrizio D, Miller VA, Stephens PJ, Fanale MA, Ross JS, Janku F. Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden. *Oncologist* 24(2):219-228, 2/2019. e-Pub 8/2018. PMID: 30108156.
70. Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, Advani RH, Newman AM, Dührsen U, Hüttmann A, Meignan M, Casasnovas O, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA. Reply to J. Wang et al. *J Clin Oncol* 37(9):755-757, 3/2019. e-Pub 2/2019. PMID: 30753108.
71. Ludmir EB, Milgrom SA, Pinnix CC, Gunther JR, Westin J, Fayad LE, Khoury JD, Medeiros LJ, Dabaja BS, Nastoupil LJ. Emerging Treatment Strategies for Primary Breast Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue. *Clin Lymphoma Myeloma Leuk* 19(4):244-250, 4/2019. e-Pub 1/2019. PMID: 30686775.
72. Xu-Monette ZY, Xiao M, Au Q, Padmanabhan R, Xu B, Hoe N, Rodríguez-Perales S, Torres-Ruiz R, Manyam GC, Visco C, Miao Y, Tan X, Zhang H, Tzankov A, Wang J, Dybkær K, Tam W, You H, Bhagat G, Hsi ED, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, van Krieken JH, Winter JN, Westin JR, Pham LV, Medeiros LJ, Rassidakis GZ, Li Y, Freeman GJ, Young KH. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. *Cancer Immunol Res* 7(4):644-657, 4/2019. e-Pub 2/2019. PMID: 30745366.
73. Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, Fayad L, Fowler NH, Cheah CY. Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement. *Br J Haematol* 185(2):334-338, 4/2019. e-Pub 7/2018. PMID: 29978452.
74. Pinnix CC, Milgrom SA, Cheah CY, Gunther JR, Ludmir EB, Wogan CF, Nastoupil LJ, Neelapu SS, Westin J, Lee HJ, Iyer SP, Steiner RE, Fayad LE, Fowler NH, Wang ML, Samaniego F, Rodriguez MA, Rich AE, Medeiros LJ, Dabaja BS. Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. *Blood Adv* 3(9):1356-1367, 5/2019. PMID: PMC6517662.
75. Nowakowski GS, Feldman T, Rimsza LM, Westin JR, Witzig TE, Zinzani PL. Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma. *Blood Cancer J* 9(6):48, 5/2019. e-Pub 5/2019. PMID: PMC6522601.
76. Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, Fayad L, Fowler NH, Cheah CY. Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival? *Ann Hematol* 98(5):1169-1176, 5/2019. e-Pub 1/2019. PMID: 30617643.
77. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Yehia Z, Nastoupil L, Romaguera J, Turturro F, Fowler N, Fayad L, Westin J, Neelapu S, Fanale MA, Rodriguez MA, Hagemeister F, Lee HJ, Oki Y, Wang M, Samaniego F, Chi L, Esmaeli B. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. *Head Neck* 41(5):1546, 5/2019. e-Pub 3/2019. PMID: 30990235.
78. Strati P, Lee ST, Teegavarupu P, Karri A, Anireddy S, Hagemeister FB, Romaguera J, Fayad LE, Rodriguez MA, Samaniego F, Fowler N, Westin J, Wang M, Lee HJ, Pinnix C, Gunther JR, Dabaja B, Feng L, Davis RE, Neelapu SS. Frontline antibiotic therapy for early-stage *Helicobacter pylori*-negative gastric MALT lymphoma. *Am J Hematol* 94(6):E150-E153, 6/2019. e-Pub 3/2019. PMID: 30785215.
79. Becnel MR, Nastoupil LJ, Samaniego F, Davis RE, You MJ, Green M, Hagemeister FB, Fanale MA, Fayad LE, Westin JR, Wang M, Oki Y, Forbes SG, Feng L, Neelapu SS, Fowler

- NH. Lenalidomide plus rituximab (R2) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. *Br J Haematol* 185(5):874-882, 6/2019. e-Pub 3/2019. PMID: 30919940.
80. Pinnix CC, Gunther JR, Milgrom SA, Cruz Chamorro RJ, Medeiros LJ, Khoury JD, Amini B, Neelapu S, Lee HJ, Westin J, Fowler N, Nastoupil L, Dabaja B. Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. *Int J Radiat Oncol Biol Phys* 104(2):447-455, 6/2019. e-Pub 2/2019. PMID: 30769175.
 81. Kurtz DM, Esfahani MS, Scherer F, Soo J, Jin MC, Liu CL, Newman AM, Dührsen U, Hüttmann A, Casasnovas O, Westin JR, Ritgen M, Böttcher S, Langerak AW, Roschewski M, Wilson WH, Gaidano G, Rossi D, Bahlo J, Hallek M, Tibshirani R, Diehn M, Alizadeh AA. Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. *Cell* 178(3):699-713.e19, 7/2019. e-Pub 7/2019. PMID: 31280963.
 82. Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Hosang CM, Oran B, Bashir Q, Olson A, Nieto Y, Alousi A, Kebriaei P, Srour S, Mehta R, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad L, Lee H, Fowler N, Parmar S, Westin J, Hagemeister F, Champlin RE, Ciurea SO. Impact of Donor Type and Melfalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. *Biol Blood Marrow Transplant* 25(7):1340-1346, 7/2019. e-Pub 2/2019. PMID: 30763728.
 83. Bishop MR, Maziarz RT, Waller EK, Jäger U, Westin JR, McGuirk JP, Fleury I, Holte H, Borchmann P, Del Corral C, Tiwari R, Anak Ö, Awasthi R, Pacaud L, Romanov VV, Schuster SJ. Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion. *Blood Adv* 3(14):2230-2236, 7/2019. PMCID: PMC6650727.
 84. Westin J. Ibrutinib and lenalidomide: when 1+1 = >2. *Blood* 134(13):996-998, 9/2019. PMID: 31558554.
 85. Myers AL, Kawedia JD, Nader A, Westin JR, Shank BR. A rare case of methotrexate and primaquine co-administration in a mantle cell lymphoma patient. *J Clin Pharm Ther* 44(5):800-804, 10/2019. e-Pub 5/2019. PMID: 31111511.
 86. Abu-Sbeih H, Tang T, Ali FS, Luo W, Neelapu SS, Westin JR, Okhuysen PC, Foo WC, Curry JL, Richards DM, Ge PS, Wang Y. Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy. *Am J Clin Oncol* 42(10):789-796, 10/2019. e-Pub 8/2019. PMID: 31478934.
 87. Sathyanarayanan V, Issa A, Pinto R, Fayad LE, Loghavi S, Hagemeister F, Westin JR. Rosai-Dorfman Disease: The MD Anderson Cancer Center Experience. *Clin Lymphoma Myeloma Leuk* 19(11):709-714, 11/2019. e-Pub 7/2019. PMID: 31446000.
 88. Strati P, Nastoupil LJ, Davis RE, Fayad LE, Fowler N, Hagemeister FB, Kwak L, Oki Y, Wang M, Westin J, Ruben CE, Wesson ET, Piekarczyk R, Fanale MA, Lee HJ. A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas. *Haematologica* 105(1):e26-e28, 1/2020. e-Pub 5/2019. PMID: 31073068.
 89. Ou A, Sumrall A, Phuphanich S, Spetzler D, Gatalica Z, Xiu J, Michelhaugh S, Brenner A, Pandey M, Kesari S, Korn WM, Mittal S, Westin J, Heimberger AB. Primary CNS lymphoma commonly expresses immune response biomarkers. *Neurooncol Adv* 2(1):vdaa018, Jan-Dec, 1/2020. e-Pub 2/2020. PMCID: PMC7067145.
 90. Gunther JR, Park C, Dabaja BS, Milgrom SA, Cruz Chamorro RJ, Medeiros LJ, Khoury JD, Garg N, Amini B, Steiner R, Nair R, Strati P, Westin JR, Lee HJ, Fowler N, Nastoupil L, Neelapu SS, Pinnix CC. Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function. *Leuk Lymphoma* 61(1):1-5, 1/2020. e-Pub 8/2019. PMID: 31373240.
 91. Hu B, Nastoupil LJ, Loghavi S, Westin JR, Thakral B, Fayad LE, Hagemeister F, Neelapu S, Samaniego F, Lee HJ, Wang ML, Fanale M, Fowler N, Oki Y. De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era. *Leuk Lymphoma* 61(2):1-9, 2/2020. e-Pub 9/2019. PMID: 31533521.
 92. Maziarz RT, Waller EK, Jaeger U, Fleury I, McGuirk J, Holte H, Jaglowski S, Schuster SJ, Bishop MR, Westin JR, Mielke S, Teshima T, Bachanova V, Foley SR, Borchmann P, Salles GA, Zhang J, Tiwari R, Pacaud LB, Ma Q, Tam CS. Patient-reported long-term quality of life

- after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. *Blood Adv* 4(4):629-637, 2/2020. PMID: PMC7042998.
93. Jain P, Zhang S, Kanagal-Shamanna R, Ok CY, Nomie K, Gonzalez GN, Gonzalez-Pagan O, Hill HA, Lee HJ, Fayad L, Westin J, Nastoupil L, Hagemeister F, Chen W, Oriabure O, Badillo M, Jiang C, Yixin Y, Li S, Tang G, Yin CC, Patel KP, Medeiros LJ, Nair R, Ahmed S, Iyer SP, Thirumurthi S, Champlin R, Xu G, Tinsu P, Santos D, Wang R, Han G, Zhang J, Song X, Neelapu S, Romaguera J, Futreal A, Flowers C, Fowler N, Wang L, Wang ML. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. *Blood Adv* 4(6):1038-1050, 3/2020. PMID: PMC7094021.
 94. Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, Han G, Hao D, Hill HA, Jiang C, Yao Y, Nastoupil L, Westin J, Fayad L, Nair R, Steiner R, Ahmed S, Samaniego F, Iyer SP, Oriabure O, Chen W, Song X, Zhang J, Badillo M, Moghrabi O, Aranda J, Tang G, Yin CC, Patel K, Medeiros LJ, Li S, Vega F, Thirumurthi S, Xu G, Neelapu S, Flowers CR, Romaguera J, Fowler N, Wang L, Wang ML, Jain P. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. *Am J Hematol* 95(6):623-629, 6/2020. e-Pub 4/2020. PMID: 32239765.
 95. Strati P, Ahmed MA, Nastoupil LJ, Feng L, Hagemeister FB, Fayad LE, Rodriguez MA, Samaniego F, Wang M, Westin JR, Lee HJ, Iyer SP, Parmar S, Ahmed S, Nair R, Steiner RE, Noorani M, Flowers CR, Davis RE, Fowler NH, Neelapu SS. Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. *Leuk Lymphoma* 61(6):1380-1387, 6/2020. e-Pub 1/2020. PMID: 31971032.
 96. Pinnix CC, Gunther JR, Dabaja BS, Strati P, Fang P, Hawkins MC, Adkins S, Westin J, Ahmed S, Fayad L, Lee HJ, Nair R, Steiner RE, Iyer SP, Rodriguez MA, Wang M, Flowers C, Neelapu SS, Nastoupil LJ. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. *Blood Adv* 4(13):2871-2883, 7/2020. PMID: PMC7362355.
 97. Strati P, Ahmed S, Kebriaei P, Nastoupil LJ, Claussen CM, Watson G, Horowitz SB, Brown ART, Do B, Rodriguez MA, Nair R, Shpall EJ, Green MR, Neelapu SS, Westin JR. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. *Blood Adv* 4(13):3123-3127, 7/2020. PMID: PMC7362369.
 98. Strati P, Ahmed MA, Fowler NH, Nastoupil LJ, Samaniego F, Fayad LE, Hagemeister FB, Romaguera JE, Rodriguez A, Wang M, Westin JR, Cheah C, Noorani M, Feng L, Davis RE, Neelapu SS. Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma. *Haematologica* 105(7):1907-1913, 7/2020. e-Pub 10/2019. PMID: PMC7327641.
 99. Strati P, Nastoupil LJ, Westin J, Fayad LE, Ahmed S, Fowler NH, Hagemeister FB, Lee HJ, Iyer SP, Nair R, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Adkins S, Claussen CM, Martinez CS, Hawkins MC, Johnson NA, Singh P, Mistry HE, Horowitz S, George S, Feng L, Kebriaei P, Shpall EJ, Neelapu SS, Tummala S, Chi TL. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. *Blood Adv* 4(16):3943-3951, 8/2020. PMID: PMC7448589.
 100. Globor G, Gunther J, Fang P, Milgrom S, Korivi BR, Jensen CT, Wagner-Bartak NA, Ahmed S, Lee HJ, Nair R, Steiner R, Parmar S, Iyer S, Westin J, Fayad L, Rodriguez MA, Neelapu S, Nastoupil L, Flowers CR, Dabaja BS, Pinnix CC. Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET-CT-documented First Remission. *Clin Lymphoma Myeloma Leuk* 20(8):533-541, 8/2020. e-Pub 2/2020. PMID: 32291233.
 101. Pinnix CC, Gunther JR, Fang P, Bankston ME, Milgrom SA, Boyce D, Lee HJ, Nair R, Steiner R, Strati P, Ahmed S, Iyer SP, Westin J, Parmar S, Rodriguez MA, Nastoupil L, Neelapu S, Flowers C, Dabaja BS. Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy. *JAMA Netw Open* 3(9):e2013935, 9/2020. e-Pub 9/2020. PMID: PMC7525355.
 102. Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Vu K, Andreadis C, Munoz J, Westin J, Chavez JC, Cashen A, Bennani NN, Rapoport AP, Vose JM, Miklos DB,

- Neelapu SS, Locke FL. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. *J Clin Oncol* 38(27):JCO1902104, 9/2020. e-Pub 5/2020. PMCID: PMC7499611.
103. Brown ART, Jindani I, Melancon J, Erfe R, Westin J, Feng L, Gutierrez C. ICU Resource Utilization in Critically Ill Patients Following Chimeric Antigen Receptor T-Cell Therapy. *Am J Respir Crit Care Med* 202(8):1184-1187, 10/2020. e-Pub 6/2020. PMCID: PMC7560798.
 104. Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen B, Dai E, Dang M, Jain N, Yang H, Wang Y, Zhang S, Wang R, Chen R, Showell J, Ghosh S, Patchva S, Zhang Q, Sun R, Hagemeister F, Fayad L, Samaniego F, Lee HC, Nastoupil LJ, Fowler N, Eric Davis R, Westin J, Neelapu SS, Wang L, Green MR. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. *Nat Med* 26(12):1878-1887, 12/2020. e-Pub 10/2020. PMID: 33020644.
 105. Chin CK, Rodriguez MA, Qing Y, Feng L, Samaniego F, Jain P, Noorani M, Fowler NH, Fayad LE, Westin JR, Neelapu SS, Hagemeister FB, Flowers CR, Nastoupil LJ. Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma. *Leuk Lymphoma* 61(12):1-5, 12/2020. e-Pub 7/2020. PMID: 32628087.
 106. Jain P, Nastoupil L, Westin J, Lee HJ, Navsaria L, Steiner RE, Ahmed S, Moghrabi O, Oriabure O, Chen W, Badillo M, Flowers CR, Wang ML. Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy. *Br J Haematol* 192(2):e38-e42, 1/2021. e-Pub 11/2020. PMID: 33152104.
 107. Strati P, Jain P, Johnson RJ, Forbes S, Feng L, Samaniego F, Rodriguez MA, Fayad LE, Hagemeister F, Westin J, Wang M, Neelapu SS, Nastoupil LJ, Fowler NH. Long Term Follow-Up of Lenalidomide and Rituximab as Initial Treatment of Follicular Lymphoma. *Blood* 137(8):1124-1129, 2/2021. e-Pub 9/2020. PMCID: PMC7907727.
 108. Fang P, Gunther JR, Pinnix CC, Dong W, Strati P, Nastoupil LJ, Steiner RE, Ahmed S, Damron EP, Fowler N, Nair R, Westin JR, Neelapu S, Ha CS, Dabaja BS. A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) Lymphoma. *Int J Radiat Oncol Biol Phys* 109(5):1414-1420, 4/2021. e-Pub 12/2020. PMID: 33309978.
 109. Joseph J, Ma J, Hennawy F, Abdulrazzaq MN, Saini N, Patel RD, Hosing CM, Alousi AM, Anderlini P, Popat UR, Qazilbash MH, Shpall EJ, Srour S, Kebriaei P, Bashir Q, Nastoupil LJ, Westin JR, Rondon G, Champlin RE, Andersson BS, Nieto Y, Muzzafar T, Ahmed S. Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. *Transplant Cell Ther* 27(5):404.e1-404.e5, 5/2021. e-Pub 2/2021. PMID: 33965178.
 110. Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Horowitz SB, Feng L, Sun R, Claussen CM, Hawkins MC, Johnson NA, Singh P, Mistry H, Johncy S, Adkins S, Kebriaei P, Shpall EJ, Green MR, Flowers CR, Westin J, Neelapu SS. Prognostic Impact of Corticosteroids on Efficacy of Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma. *Blood* 137(23):3272-3276, 6/2021. e-Pub 2/2021. PMCID: PMC8351896.
 111. Augustyn A, Medeiros LJ, Ludmir EB, Gunther J, Fang P, Li S, Ok CY, Bankston ME, Verma V, Pasalic D, Ahmed S, Nastoupil LJ, Westin JR, Strati P, Neelapu SS, Nair R, Steiner RE, Iyer SP, Rodriguez A, Fayad LE, Flowers CR, Dabaja BS, Pinnix CC. The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. *Leuk Lymphoma* 62(6):1-12, 6/2021. e-Pub 1/2021. PMCID: PMC8262455.
 112. Chheng HJ, Westin J. Why R-CHOP?+?X is not enough: lessons learned and next steps in the mission to improve frontline therapy for diffuse large B-cell lymphoma. *Leuk Lymphoma* 62(6):1-17, 6/2021. e-Pub 1/2021. PMID: 33403905.
 113. Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers CR, Tummala S, Ramdial JL, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. *Blood Adv* 5(14):2799-2806, 7/2021. PMCID: PMC8341350.

114. Alig S, Macaulay CW, Kurtz DM, Dührsen U, Hüttmann A, Schmitz C, Jin MC, Sworder BJ, Garofalo A, Shahrokh Esfahani M, Nabet BY, Soo J, Scherer F, Craig AFM, Casasnovas O, Westin JR, Gaidano G, Rossi D, Roschewski M, Wilson WH, Meignan M, Diehn M, Alizadeh AA. Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma. *J Clin Oncol* 39(23):JCO2002573, 8/2021. e-Pub 4/2021. PMID: PMC8331064.
115. Westin JR, Kersten MJ, Salles G, Abramson JS, Schuster SJ, Locke FL, Andreadis C. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials. *Am J Hematol* 96(10):1295-1312, 10/2021. e-Pub 8/2021. PMID: 34310745.
116. Strati P, Varma A, Adkins S, Nastoupil LJ, Westin J, Hagemeister FB, Fowler NH, Lee HJ, Fayad LE, Samaniego F, Ahmed S, Chen Y, Horowitz S, Arafat S, Johncy S, Kebriaei P, Mulanovich VE, Ariza Heredia E, Neelapu SS. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. *Haematologica* 106(10):2667-2672, 10/2021. e-Pub 10/2021. PMID: PMC8485681.
117. Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu JM, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Martinez-Prieto M, Han X, Tiwari R, Salles G, Maziarz RT. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. *Lancet Oncol* 22(10):1403-1415, 10/2021. e-Pub 9/2021. PMID: 34516954.
118. Al Feghali KA, Fang P, Gule-Monroe M, Milgrom S, Khoury JD, Gunther JR, Sheu T, Nair R, Ahmed S, Steiner R, Strati P, Shpall EJ, Nieto YL, Hosing C, Nastoupil LJ, Westin JR, Neelapu SS, Fowler N, Flowers C, Pinnix CC, Dabaja BS. Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy. *Leuk Lymphoma* 62(10):1-8, 10/2021. e-Pub 5/2021. PMID: 33942701.
119. Gordon MJ, Westin JR. Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole? *Leuk Lymphoma*:1-11. e-Pub 11/2021. PMID: 34842019.
120. Rutherford SC, Abramson JS, Bartlett NL, Barta SK, Khan N, Joyce R, Maddocks K, Ali-Shaw T, Senese S, Yuan Y, Westin J, Leonard JP. Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study. *Lancet Haematol* 8(11):e818-e827, 11/2021. e-Pub 10/2021. PMID: 34634256.
121. Kurtz DM, Soo J, Co Ting Keh L, Alig S, Chabon JJ, Sworder BJ, Schultz A, Jin MC, Scherer F, Garofalo A, Macaulay CW, Hamilton EG, Chen B, Olsen M, Schroers-Martin JG, Craig AFM, Moding EJ, Esfahani MS, Liu CL, Dührsen U, Hüttmann A, Casasnovas RO, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. *Nat Biotechnol* 39(12):1537-1547, 12/2021. e-Pub 7/2021. PMID: PMC8678141.
122. Nastoupil LJ, Neelapu SS, Davis RE, Samaniego F, Fowler NH, Westin J, Lee HJ, Wang M, Hagemeister F, Cecil ARL, Dow J, Haque K, Silva FA, Whale A, Lensun L, Bone EA, McElwaine-Johnn H, Beer PA. Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma. *Leuk Lymphoma* 62(14):1-11, 12/2021. e-Pub 8/2021. PMID: 34365878.
123. Chheng HJ, Chuang HH, Steiner R, Fayad L, Strati P, Nair R, Hagemeister F, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Samaniego F, Rodriguez M, Macapinlac HA, Feng L, Westin J. A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. *Leuk Lymphoma* 63(1):1-10, 1/2022. e-Pub 8/2021. PMID: 34435552.
124. Gutierrez C, Brown ART, May HP, Beitinjane A, Stephens RS, Rajendram P, Nates JL, Pastores SM, Dharshan A, de Moraes AG, Hensley MK, Feng L, Brudno JN, Athale J, Ghosh M, Kochenderfer JN, Arias AS, Lin Y, McEvoy C, Mead E, Westin J, Kostecky N, Mian A, Herr MM. Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study. *Crit Care Med* 50(1):81-92, 1/2022. e-Pub 7/2021. PMID: PMC8678137.

125. Westin J, Maris MB, Jacobson CA, Patel P, Lakhani N, Harb W, Patel-Donnelly D, McCaul K, Escobar C, Klencke B, Al-Katib AM. Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *Clin Lymphoma Myeloma Leuk* 22(1):52-59, 1/2022. e-Pub 7/2021. PMID: 34454850.
126. Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Muñoz J, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR, All ZUMA-7 Investigators and Contributing Kite Members. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. *N Engl J Med* 386(7):640-654, 2/2022. e-Pub 12/2021. PMID: 34891224.
127. Nastoupil LJ, Chin CK, Westin JR, Fowler NH, Samaniego F, Cheng X, Ma MCJ, Wang Z, Chu F, Dsouza L, Obi C, Mims J, Feng L, Zhou S, Green M, Davis RE, Neelapu SS. Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma. *Blood Adv* 6(4):1143-1151, 2/2022. e-Pub 1/2022. PMCID: PMC8864656.
128. Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, Morschhauser F, Janz M, Flinn I, Rabitsch W, Kwong YL, Kersten MJ, Minnema MC, Holte H, Chan EHL, Martinez-Lopez J, Müller AMS, Maziarz RT, McGuirk JP, Bachy E, Le Gouill S, Dreyling M, Harigae H, Bond D, Andreadis C, McSweeney P, Kharfan-Dabaja M, Newsome S, Degtyarev E, Awasthi R, Del Corral C, Andreola G, Masood A, Schuster SJ, Jäger U, Borchmann P, Westin JR. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. *N Engl J Med* 386(7):629-639, 2/2022. e-Pub 12/2021. PMID: 34904798.
129. Westin J. Always be prepared for success. *Blood* 139(13):1928-1930, 3/2022. PMID: 35357477.
130. Wang ML, Jain P, Zhao S, Lee HJ, Nastoupil L, Fayad L, Ok CY, Kanagal-Shamanna R, Hill HA, Yao Y, Hagemeister FB, Westin JR, Fowler N, Samaniego F, Steiner R, Nair R, Iyer SP, Navsaria L, Badillo M, Mantle Cell Research Group, Feng L, Xuelin H, Nogueras Gonzalez GM, Xu G, Wagner-Bartak N, Thirumurthi S, Santos D, Tang G, Lin P, Wang SA, Jorgensen J, Yin CC, Li S, Patel KP, Vega F, Medeiros LJ, Flowers CR, Wang L. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤ 65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. *Lancet Oncol* 23(3):406-415, 3/2022. e-Pub 1/2022. PMID: 35074072.
131. Ma MCJ, Tadros S, Bouska A, Heavican T, Yang H, Deng Q, Moore D, Akhter A, Hartert K, Jain N, Showell J, Ghosh S, Street L, Davidson M, Carey C, Tobin J, Perumal D, Vose JM, Lunning MA, Sohani AR, Chen BJ, Buckley S, Nastoupil LJ, Davis RE, Westin JR, Fowler NH, Parekh S, Gandhi M, Neelapu S, Stewart D, Bhalla K, Iqbal J, Greiner T, Rodig SJ, Mansoor A, Green MR. Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. *Haematologica* 107(3):690-701, 3/2022. e-Pub 3/2022. PMCID: PMC8883549.
132. Akin S, Hosing C, Khouri I, Ahmed S, Alousi A, Fowler N, Joseph J, Truxillo J, Ramdial JL, Maadani F, Rondon G, Daher M, Im JS, Steiner R, Westin J, Iyer SP, Dabaja B, Anderlini P, Popat UR, Qazilbash MH, Flowers CR, Shpall E, Champlin RE, Nieto Y, Srour SA. Autologous Stem Cell Transplantation for Large B-cell Lymphoma with Secondary Central Nervous System Involvement. *Blood Adv* 6(7):2267-2274, 4/2022. e-Pub 1/2022. PMCID: PMC9006305.
133. Westin J, Sehn LH. CAR T-cells as a second-line therapy of large B-cell lymphoma: A paradigm shift? *Blood* 139(18):2737-2746, 5/2022. e-Pub 3/2022. PMID: 35240677.
134. Al Zaki A, Feng L, Watson G, Ahmed SA, Mistry H, Nastoupil LJ, Hawkins M, Nair R, Iyer SP, Lee HJ, Steiner RE, Flowers CR, Shpall EJ, Kebriaei P, Neelapu SS, Westin JR, Strati P. Day 30 SUVmax Predicts Progression in Lymphoma Patients Achieving PR/SD After CAR T-cell Therapy. *Blood Adv* 6(9):2867-2871, 5/2022. e-Pub 1/2022. PMID: 35015825.
135. Harkins RA, Patel SP, Lee MJ, Switchenko JM, Ansell SM, Bartlett NL, Blum KA, Cashen AF, Casulo C, Friedberg JW, Johnston PB, Kahl BS, Leonard JP, Link BK, Lossos IS, Martin P, Maurer MJ, Mehta-Shah N, Reagan PM, Westin JR, Koff JL, Flowers CR. Improving eligibility

- criteria for first-line trials for patients with DLBCL using a U.S.-based Delphi-method survey. *Blood Adv* 6(9):2745-2756, 5/2022. e-Pub 1/2022. PMID: 35100356.
136. Marques-Piubelli ML, Parra ER, Feng L, Soto LS, Gallardo M, Gouni S, Samaniego F, Noorani M, Hagemeister FB, Westin JR, Lee HJ, Rodriguez MA, Neelapu SS, Gunther JR, Fowler NH, Flowers CR, Wistuba II, Nastoupil LJ, Vega F, Strati P. SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab. *Blood Adv* 6(11):3286-3293, 6/2022. e-Pub 3/2022. PMCID: PMC9198921.
 137. Steiner RE, Banchs J, Koutroumpakis E, Becnel M, Gutierrez C, Strati P, Pinnix CC, Feng L, Rondon G, Claussen C, Palaskas N, Karimzad K, Ahmed S, Neelapu SS, Shpall E, Wang M, Vega F, Westin J, Nastoupil LJ, Deswal A. Cardiovascular events in patients treated with chimeric antigen receptor t-cell therapy for aggressive B-cell lymphoma. *Haematologica* 107(7):1555-1566, 7/2022. e-Pub 7/2022. PMCID: PMC9244830.
 138. Palomba ML, Cartron G, Popplewell L, Ribrag V, Westin J, Huw LY, Agarwal S, Shivhare M, Hong WJ, Raval A, Chang AC, Penuel E, Morschhauser F. Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study. *Clin Lymphoma Myeloma Leuk* 22(7):504-512, 7/2022. e-Pub 12/2021. PMID: 35151584.
 139. Jaeger U, Tam CS, Borchmann P, McGuirk JP, Johansen M, Waller EK, Jaglowski S, Andreadis C, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Salles G, Schuster SJ, He F, Maziarz RT, Mayer S, Makita S, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Goto H, Colicino S, Agarwal A, Lobetti-Bodoni C, Bishop MR. Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma. *Blood Adv* 6(16):4816-4820, 8/2022. e-Pub 6/2022. PMID: 35687492.
 140. Cherng HJ, Sun R, Sugg B, Irwin R, Yang H, Le CC, Deng Q, Fayad L, Fowler NH, Parmar S, Steiner R, Hagemeister F, Nair R, Lee HJ, Rodriguez M, Samaniego F, Iyer SP, Flowers CR, Wang L, Nastoupil LJ, Neelapu SS, Ahmed S, Strati P, Green MR, Westin J. Risk assessment with low pass whole genome sequencing of cell free DNA before CD19 CAR T-cells for large B-cell lymphoma. *Blood* 140(5):504-515, 8/2022. e-Pub 5/2022. PMID: 35512184.
 141. Cherng HJ, Westin JR. Broadening the MIND: tafasitamab and lenalidomide versus synthetic controls. *Clin Cancer Res* 28(18):3908-3910, 9/2022. e-Pub 7/2022. PMCID: PMC9481674.
 142. Saini NY, Swoboda DM, Greenbaum U, Ma J, Patel RD, Devashish K, Das K, Tanner MR, Strati P, Nair R, Fayad L, Ahmed S, Lee HJ, Iyer SP, Steiner R, Jain N, Nastoupil L, Loghavi S, Tang G, Bassett RL, Jain P, Wang M, Westin JR, Green MR, Sallman DA, Padron E, Davila ML, Locke FL, Champlin RE, Garcia-Manero G, Shpall EJ, Kebriaei P, Flowers CR, Jain MD, Wang F, Futreal AP, Gillis N, Neelapu SS, Takahashi K. Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma. *Blood Cancer Discov* 3(5):385-393, 9/2022. e-Pub 5/2022. PMCID: PMC9445749.
 143. Han G, Deng Q, Marques-Piubelli ML, Dai E, Dang M, Ma MCJ, Li X, Yang H, Henderson J, Kudryashova O, Meerson M, Isaev S, Kotlov N, Nomie KJ, Bagaev A, Parra ER, Solis Soto LM, Parmar S, Hagemeister FB, Ahmed S, Iyer SP, Samaniego F, Steiner R, Fayad L, Lee H, Fowler NH, Flowers CR, Strati P, Westin JR, Neelapu SS, Nastoupil LJ, Vega F, Wang L, Green MR. Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression. *Blood Cancer Discov* 3(5):428-443, 9/2022. e-Pub 6/2022. PMID: 35687817.
 144. Fahrman JF, Saini NY, Chia-Chi C, Irajizad E, Strati P, Nair R, Fayad LE, Ahmed S, Lee HJ, Iyer S, Steiner R, Vykoukal J, Wu R, Dennison JB, Nastoupil L, Jain P, Wang M, Green M, Westin J, Blumenberg V, Davila M, Champlin R, Shpall EJ, Kebriaei P, Flowers CR, Jain M, Jenq R, Stein-Thoeringer CK, Subklewe M, Neelapu SS, Hanash S. A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma. *Cell Rep Med* 3(11):100720, 11/2022. PMID: 36384092.
 145. Chiu CY, Zhang HC, Westin J, Hosing C, Torres HA. Hepatitis E Virus Infection in Cancer Patients. *Transplant Cell Ther* 28(11):788.e1-788.e5, 11/2022. e-Pub 8/2022. PMID: 36031077.

146. Strati P, Jallouk AP, Sun R, Choi J, Das K, Cherng HJ, Ahmed S, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Steiner RE, Huff CD, Yu Y, Mistry H, Pulsifer B, Noorani M, Saini N, Shpall EJ, Kebriaei P, Flowers CR, Westin JR, Hildebrandt MAT, Neelapu SS. Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy. *Leukemia* 36(11):2669-2677, 11/2022. e-Pub 9/2022. PMID: 36127509.
147. Sworder BJ, Kurtz DM, Alig SK, Frank MJ, Shukla N, Garofalo A, Macaulay CW, Shahrokh Esfahani M, Olsen MN, Hamilton J, Hosoya H, Hamilton M, Spiegel JY, Baird JH, Sugio T, Carleton M, Craig AFM, Younes SF, Sahaf B, Sheybani ND, Schroers-Martin JG, Liu CL, Oak JS, Jin MC, Beygi S, Hüttmann A, Hanoun C, Dührsen U, Westin JR, Khodadoust MS, Natkunam Y, Majzner RG, Mackall CL, Diehn M, Miklos DB, Alizadeh AA. Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. *Cancer Cell* 41(1):210-225.e5, 1/2023. e-Pub 12/2022. PMCID: PMC10010070.
148. Cherng HJ, Xu G, Feng L, Steiner R, Fayad L, Strati P, Nair R, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Rodriguez M, Wang M, Hagemester F, Pinnix CC, Ramdial J, Srour S, Nieto Y, Rezvani K, Champlin R, Kebriaei P, Westin J, Macapinlac HA, Shpall E, Ahmed S. Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant. *Br J Haematol* 200(1):35-44, 1/2023. e-Pub 9/2022. PMCID: PMC9771924.
149. Westin J, Davis RE, Feng L, Hagemester F, Steiner R, Lee HJ, Fayad L, Nastoupil L, Ahmed S, Rodriguez A, Fanale M, Samaniego F, Iyer SP, Nair R, Oki Y, Fowler N, Wang M, Ma MCJ, Vega F, McDonnell T, Pinnix C, Griffith D, Lu Y, Tewari S, Sun R, Scott DW, Flowers CR, Neelapu S, Green MR. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. *J Clin Oncol* 41(4):JCO2200597, 2/2023. e-Pub 8/2022. PMID: 35952327.
150. Steiner RE, Parra ER, Vega F, Feng L, Westin JR, Neelapu SS, Strati P, Green MR, Flowers CR, Solis LM, Wistuba II, Ahmed S, Nair R, Hagemester FB, Noorani M, Marques-Piubelli ML. PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma. *Exp Hematol Oncol* 12(1):32, 3/2023. e-Pub 3/2023. PMCID: PMC10026479.
151. Stein-Thoeringer CK, Saini NY, Zamir E, Blumenberg V, Schubert ML, Mor U, Fante MA, Schmidt S, Hayase E, Hayase T, Rohrbach R, Chang CC, McDaniel L, Flores I, Gaiser R, Edinger M, Wolff D, Heidenreich M, Strati P, Nair R, Chihara D, Fayad LE, Ahmed S, Iyer SP, Steiner RE, Jain P, Nastoupil LJ, Westin J, Arora R, Wang ML, Turner J, Menges M, Hidalgo-Vargas M, Reid K, Dreger P, Schmitt A, Müller-Tidow C, Locke FL, Davila ML, Champlin RE, Flowers CR, Shpall EJ, Poeck H, Neelapu SS, Schmitt M, Subklewe M, Jain MD, Jenq RR, Elinav E. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. *Nat Med* 29(4):906-916, 4/2023. e-Pub 3/2023. PMCID: PMC10121864.
152. Cherng HJ, Alig SK, Oki Y, Nastoupil LJ, Fayad L, Neelapu SS, Turturro F, Hagemester F, Craig AFM, Macaulay CW, Rodriguez MA, Lee HJ, McDonnell TJ, Flowers CR, Vega F, Green MR, Feng L, Kurtz DM, Alizadeh AA, Davis RE, Westin JR. A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. *Blood Adv* 7(7):1137-1145, 4/2023. e-Pub 11/2022. PMCID: PMC10111343.
153. Jallouk AP, Gouni S, Westin J, Feng L, Mistry H, Steiner RE, James J, Noorani M, Horowitz S, Puebla-Osorio N, Fayad LE, Iyer SP, Hawkins M, Flowers CR, Ahmed S, Nastoupil LJ, Kebriaei P, Shpall EJ, Neelapu SS, Nieto Y, Strati P. Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response. *Haematologica* 108(4):1163-1167, 4/2023. e-Pub 4/2023. PMCID: PMC10071112.
154. Gurumurthi A, Westin JR, Subklewe M. The race is on: bispecifics vs CAR T-cells in B-cell lymphoma. *Blood Adv*. e-Pub 4/2023. PMID: 37037004.
155. Westin JR, Locke FL, Dickinson M, Ghobadi A, Elsayy M, van Meerten T, Miklos DB, Ulrickson ML, Perales MA, Farooq U, Wannesson L, Leslie L, Kersten MJ, Jacobson CA, Pagel JM, Wulf G, Johnston P, Rapoport AP, Du L, Vardhanabhuti S, Filosto S, Shah J, Snider JT, Cheng P, To C, Oluwole OO, Sureda A. Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with

- Relapsed/Refractory Large B-Cell Lymphoma. Clin Cancer Res 29(10):1894-1905, 5/2023. PMID: PMC10183830.
156. Strati P, Jallouk A, Deng Q, Li X, Feng L, Sun R, Adkins S, Johncy S, Cain T, Steiner RE, Ahmed S, Chihara D, Fayad LE, Padmanabhan Iyer S, Horowitz SB, Nastoupil LJ, Nair R, Hassan A, Daoud T, Hawkins M, Rodriguez MA, Shpall EJ, Ramdial JL, Kebriaei P, Hong DS, Westin JR, Neelapu SS, Green MR. A Phase I Study of Prophylactic Anakinra to Mitigate ICANS in Patients with Large B-cell Lymphoma. Blood Adv. e-Pub 6/2023. PMID: 37389847.
 157. Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, Rapoport AP, Sureda A, Jacobson CA, Farooq U, van Meerten T, Ulrickson M, Elsayy M, Leslie LA, Chaganti S, Dickinson M, Dorritie K, Reagan PM, McGuirk J, Song KW, Riedell PA, Minnema MC, Yang Y, Vardhanabhuti S, Filosto S, Cheng P, Shahani SA, Schupp M, To C, Locke FL, ZUMA-7 Investigators, Kite Members. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. N Engl J Med 389(2):148-157, 7/2023. e-Pub 6/2023. PMID: 37272527.
 158. Olszewski AJ, Phillips TJ, Hoffmann MS, Armand P, Kim TM, Yoon DH, Mehta A, Greil R, Westin JR, Lossos IS, Munoz J, Sit J, Wei MC, Yang A, Chen V, Purev E, Yee DL, Jaeger U. Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study. Blood Adv. e-Pub 8/2023. PMID: 37581593.
 159. Strati P, Li X, Deng Q, Marques-Piubelli ML, Henderson J, Watson G, Deaton L, Cain T, Yang H, Ravanmehr V, Fayad LE, Iyer SP, Nastoupil LJ, Hagemester FB, Parra ER, Saini N, Takahashi K, Fowler NH, Westin JR, Steiner RE, Nair R, Flowers CR, Wang L, Ahmed S, Al-Atrash G, Vega F, Neelapu SS, Green MR. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFN γ -expressing CD8 T cells. Cell Rep Med 4(8):101158, 8/2023. PMID: PMC10439270.

Invited Articles

N/A

Editorials

1. Westin J, Hagemester F. R-CHOP every 21 days for diffuse large B-cell lymphoma: still the standard of care? J Comp Eff Res 2(6):537-40, 11/2013. PMID: 24236792.
2. Westin JR. Busting robustness: using cancer's greatest strength to our advantage. Future Oncol. e-Pub 3/2014. PMID: 24673642.

Other Articles

N/A

Abstracts

1. Westin J., Saliba R., de Lima M, Alousi A., Hosing C., Qazilbash M, Khouri I., Shpall E., Champlin R. Couriel, D. Risk Factors for Response after Initial Therapy for Acute Graft-Versus-Host-Disease (aGVHD). Blood (ASH Annual Meeting Abstracts) 110:Abstract 5015, 2007.
2. Westin J., Thompson M., Cataldo V, Toth B, Sanjorjo P, Bourgeois S, Jimenez C, Murphy W, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, Hagemester F. Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response. Blood (ASH Annual Meeting Abstracts) 114:Abstract 3922, 2009.
3. Westin J., Thompson M., Cataldo V, Toth B, Sanjorjo P, Bourgeois S, Jimenez C, Murphy W, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, Hagemester F. The Effect of Zoledronic Acid on the Prevention of Bone Loss in Lymphoma Patients Receiving First-line Therapy. Clin Lymphoma Myeloma 9((6)):E30, 2009.
4. Westin J., Thompson M., Cataldo V, Toth B, Sanjorjo P, Bourgeois S, Jimenez C, Murphy W, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, Hagemester F. Bone Loss in Lymphoma Patients Prior to Receiving Frontline Therapy. Presented at the 2010 14th Annual International Congress on Hematologic Malignancies, 2010.
5. Westin J., Chu F., Foglietta, M., Rodionov G., Rotem-Yehudar R., Neelapu SS. Phase II safety and efficacy study of CT-011, a humanized anti-PD-1 monoclonal antibody, in

- combination with rituximab in patients with relapsed follicular lymphoma. *J Clin Oncol* 28(suppl TPS305), 2010.
6. Westin J., Thompson M., Cataldo V, Toth B, Sanjorjo P, Bourgeois S, Jimenez C, Murphy W, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, Hagemester F. The effect of zoledronic acid on the prevention of bone loss in lymphoma patients receiving first-line therapy. *J Clin Oncol* 28(no. 15_suppl 9103), 2010.
7. Westin J., Thompson M., Cataldo V, Toth B, Sanjorjo P, Bourgeois S, Jimenez C, Murphy W, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, Hagemester F. Zoledronic acid treatment of frontline lymphoma patients; Prevention of bone loss. Poster presentation at the Hematologic Malignancies 2010 - Sixth International Conference, 2010.
8. Westin J., Fu S., Hong D., Helgason T., Culotta C., Angelo L., Ouyang F., Westin S., Kurzrock R. Validation of the Phase 0 Concept. *J Clin Oncol* 29:(suppl; abstr TPS143), 2011.
9. Chu F., Westin J., Zhang M, Feng L, Baladandayuthapani V, Wang Z., Allen R, Wallace M., Vence LM, Radvanyi L, Kwak LW, Rotem-Yehudar R, Davis RE, and Neelapu SS. Immunological Effects and Predictive Gene Signatures in Patients with Relapsed Follicular Lymphoma treated with CT-011, a Humanized anti-PD-1 Monoclonal. *Blood (ASH Annual Meeting Abstracts)* 120:Abstract 162, 2012.
10. Westin J., Chu F., Fayad L, Kwak LW, Fowler NH, Romaguera J., Hagemester FB, Fanale M, Samaniego F, Allen R, Feng L, Baladandayuthapani V, Rotem-Yehudar R, and Neelapu SS. Phase II Safety and Efficacy Study of CT-011, a Humanized anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma. *Blood (ASH Annual Meeting Abstracts)* 120:Abstract 793, 2012.
11. Oki Y., Westin J., Fowler N, Neelapu S, McLaughlin P, Kwak LW, Romaguera J, Fanale M, Rodriguez MA, Orlowski RZ, Wang M, Ouzanian S. R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL. *Blood (ASH Annual Meeting Abstracts)* 12:Abstract 3707, 2012.
12. Westin J., Chu F., Fayad L, Kwak LW, Fowler NH, Romaguera J., Hagemester FB, Fanale M, Samaniego F, Allen R, Feng L, Baladandayuthapani V, Rotem-Yehudar R, and Neelapu SS. Final Update of Phase II Safety and Efficacy Study of CT-011, a Humanized anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma. *Hematological Oncology Volume 31(Issue S1)*, 6/2013.
13. Fanale MA, Westin JR, Fowler N, Neelapu SS, Hagemester FB, Rodriguez MA, Younes A. A Phase I Study Of Panobinostat In Combination With ICE (Ifosfamide, Carboplatin and Etoposide) In Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma (cHL). *Blood (ASH Annual Meeting Abstracts)* 122(21):252, 12/2013.
14. Flinn I, Berdeja J, Friedberg JW, Casulo C, Thieblemont C, Morschhauser F, Westin JR, Seetharam S, Hellemans P, Smit H, de Vries R, Dauphinee E, Badamo-Dotzis J, Fourneau N, Oki Y. Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP): Updated Results From a Phase 1b Study in Patients With CD20-Positive B-Cell non-Hodgkin's lymphoma (NHL). *Blood (ASH Annual Meeting Abstracts)* 2013 122(21):852, 12/2013.
15. Noorani M, Davis RE, Neelapu SS, Rodriguez A, Hagemester FB, Fowler N, Wang M, Fanale MA, Samaniego F, Dabaja BS, Pinnix C, Kwak LW, Romaguera JE, Khouri I, Westin JR, Fayad LE. Double Hit Lymphoma: M.D. Anderson Experience Submitted. *Blood (ASH Annual Meeting Abstracts)* 2013 122(21):1776, 12/2013.
16. Jason R. Westin, Min Zhang, Seema Rawal, Larry W. Kwak, Sattva S. Neelapu, and R. Eric Davis. Integrated Analysis Of Genomic and Gene Expression Profiles In Follicular Lymphoma Reveals Subsets and Driver Genes Of Potential Microenvironmental Importance. *Blood (ASH Annual Meeting Abstracts)* 2013 122(21):2487, 12/2013.
17. Romaguera JE, Kwak LW, Hagemester FB, Rodriguez MA, Oki Y, Westin JR, Turturro F, Overman MJ, Neelapu SS, Fowler N, Fayad LE. Long-Term Remissions of Patients with Follicular Lymphoma Grade 3 Treated with Rituximab, Cyclophosphamide, Doxorubicine, Vincristine and Prednisone (R-CHOP). *Blood (ASH Annual Meeting Abstracts)* 2013 122(21):3028, 12/2013.

18. Saliba RM, Xu-Monette ZY, Rondon G, Valverde R, Korbling M, Gulbis AM, Anderlini P, Sairah A, Hosing CM, Popat UR, Kebriaei P, Fayad LE, Westin JR, Turturro F, Medeiros LJ, Champlin RE, Young KH. Outcomes following Autologous Stem Cell Transplantation (ASCT) in Patients with Germinal Center B (GCB) and non-GCB Cell-Like Diffuse Large B cell Lymphomas (DLBCL) According to Conditioning with BEAM-Rituximab (Standard vs. High-Dose) vs. BEAM/Yttrium-90 Ibritumomab Tiuxetan (90YIT). Blood (ASH Annual Meeting Abstracts) 2013 122(21):3350, 12/2013.
19. Garrido-Laguna I, Velez-Bravo V, Falchook GS, Subbiah V, Hong DS, Oki Y, Westin JR, Nunez CA, Fayad LE, Kwak LW, Shpall EJ, Wheeler JJ, Liang W, Salhia B, Meric-Bernstam F, Kurzrock R, Fanale MA. Significant activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients. Blood (ASH Annual Meeting Abstracts) 2013 122(21):3048, 12/2013.
20. Nastoupil LJ, Neelapu SS, Samaniego F, Hagemester FB, Romaguera JR, Kwak LW, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, McLaughlin P, Fowler NH. 10-year remission rates following rituximab (R) and FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) with interferon (IFN) maintenance in indolent lymphoma: Results of a randomized study. J Clin Oncol 32:5s,((suppl; abstr 8528)). e-Pub 6/2014.
21. Janku F, Oki Y, Falchook GS, Subbiah V, Naing A, Bravo VMV, Hong DS, Westin JR, Nunez C, Fayad L, Neelapu SS, Kwak LW, Shpall EJ, Wheeler JJ, Barnes T, Liang WS, Salhia B, Meric-Bernstam F. Activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients. J Clin Oncol 32:5s, 2014:(suppl; abstr 8508). e-Pub 6/2014.
22. Ahmed MA, Barac R, Medeiros LJ, Ma L, Fayad L, Romaguera JE, Oki Y, Rodriguez MA, Pinnix C, Kwak LW, Hagemester FB, Davis RE, Westin JR. Treatment outcomes and prognostic factors for primary mediastinal B-cell lymphoma: The MD Anderson experience. J Clin Oncol 32:5s:(suppl; abstr 8564). e-Pub 6/2014.
23. Fayad L, Rodriguez A, Samaniego F, Fowler N, Oki Y, Turturro F, Westin J, Kwak L, Sabaja B, Feng L, Davis RE, Neelapu S. Antibiotic Therapy of H. Pylori negative Gastric MALT Lymphoma. Blood (ASH Annual Meeting Abstracts 2014) 124(21), 12/2014.
24. Hagemester F, Westin J, Fayad L, Samaniego F, Turturro F, Chen W, Zhang L, Badillo M. Ibrutinib and Rituximab are an Efficacious and Safe Combination in Relapsed Mantel Cell Lymphoma: Preliminary Results from a Phase II Clinical Trial. Blood (ASH Annual Meeting Abstracts 2014) 124(21), 12/2014.
25. Ahmed S, Ciurea SO, Fayad L, Oran B, Parmar S, Popat U, Westin J, Turturro F, Medeiros LJ, Gulbis AM, Young KH. Outcomes Following Allogenic Stem Cell Transplantation (AlloSCT) in Patients with Primary Mediastinal (PMBL) Germinal Center B (GCB) and Non-GCB Cell-like Diffuse Large B-Cell Lymphomas (DLBCL). Blood (ASH Annual Meeting Abstracts 2014) 124(21), 12/2014.
26. Rodriguez A, Samaniego F, Fanale M, Wang M, Oki Y, Turturro F, Westin J, Nastoupil L, Kwak L, David RE, Neelapu S. R-Bendamustine vs. R-CHOP as Initial Treatment for Advanced Stage Low Grade Follicular Lymphoma: A Matched-Pair Analysis. Blood (ASH Annual Meeting Abstracts 2014) 124(21), 12/2014.
27. Xu J, David RE, Zhiqiang Wang, Westin J. Selinexor (KPT-330) is Not Cross-Resistant with Chemotherapy and Demonstrates Strong Synergy with Targeted Therapy in DLBCL. Blood (ASH Annual Meeting Abstracts 2014) 124(21), 12/2014.
28. Rodriguez A, Samaniego F, Fanale M, Wang M, Oki Y, Turturro F, Westin J, Kwak L, Nastoupil L, Cheah C, Feng L, Rohren E. SUVmax on Pre-Treatment FDG PET Scan is Not Predictive of Outcome in Follicular Lymphoma after R-CHOP Therapy. Blood (ASH Annual Meeting Abstracts 2014) 124(21), December 6, 2014, 12/2014.
29. Havranek O, Koehrer S, Xu J, Becker L, Comer J, Karri A, Wang Z, Ma W, Westin J, Sal T, Burger J, Davis RE. B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma: Tonic Alone in the Germinal B-Cell Subtype, Plus Self Antigen-induced in the Activated B-Cell Subtype. Blood (2015 ASH Annual Meeting) 126(123), 12/2015.
30. Chihara D, Oki Y, Westin J, Nastoupil L, Fayad L, Samaniego F, Wesson E, Ruben C, Horowitz S, Feng L, Garg N, Ahmed S, Khouri I, Hosing C, Romaguera J, Fowler N, Fanale

- M. High Response Rate of Romidepsin in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Updates of Phase I Trial. *Blood* (2015 ASH Annual Meeting) 126(123), 12/2015.
31. Khouri I, Sui D, Turturro F, Erwin W, Basset R, Korbling M, Valverde R, Ahmed S, Alousi A, Anderlini P, Bashir Q, Cuirena S, Oran B, Olson A, Popat U, Patel K, Qazilbash M, Fanale M, Fayad L, Nastoupil L, Westin J, Gulbis A, Medeiros J, Young K, Jessop A. In-Vivo Purging with Rituximab (R) Followed by Z/BEAM vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials. *Blood* (2015 ASH Annual Meeting) 126(123), 12/2015.
 32. Chihara D, Ahmed M, Oki Y, Westin J, Hagemeister F, Romaguera J, Fanale M, Lee HJ, Turturro F, Samaniego F, Neelapu S, Rodriguez A, Fowler N, Wang M, Fayad L, Davis RE, Nastoupil L. Management Strategies and Outcomes for Very Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL). *Blood* (2015 ASH Annual Meeting) 126(123), 12/2015.
 33. Galamina N, Smith S, Liao C, Petrick A, Libao B, Gartenhaus R, Westin J, Cohen K, Knost J, Stadler W, Doyle A, Karrison T, Gordon L, Evens A. Selective MEK Inhibition with AZD-6244 (selumetinib) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A University of Chicago Phase II Consortium Trial. *Blood* (2015 ASH Annual Meeting) 126(123), 12/2015.
 34. Ahmed M, Oki Y, Noorani M, Nastoupil L, Fayad L, Hagemeister F, Rodriguez A, Davis RE, Westin J. The Clinical Outcome of Newly Diagnosed Patients >60 Years of Age with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Standard or Liposomal Chemotherapies. *Blood* (2015 ASH Annual Meeting) 126(123), 12/2015.
 35. Chihara D, Fanale M, Noorani M, Westin J, Nastoupil L, Hagemeister F, Fayad L, Romaguera J, Samaniego F, Turturro F, Lee HJ, Neelapu S, Rodriguez A, Wang M, Fowler N, Miranda R, Hosing C, Nieto Y, Davis RE, Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma. *Blood* (2015 ASH Annual Meeting) 126(123), 12/2015.
 36. Chihara D, Fanale M, Noorani M, Westin J, Nastoupil L, Hagemeister F, Fayad L, Romaguera J, Samaniego F, Turturro F, Lee JL, Neelapu S, Rodriguez A, Wang M, Fowler N, Miranda R, Hosing C, Nieto Y, Davis RE, Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL. *Blood* (2015 ASH Annual Meeting) 126(123), 12/2015.
 37. Westin JR, Maris MB, Al-Katib AM, Lakhani NJ, Patel PA, Harb WA, McCaul K, Patel-Donnelly D, Messmann RA, Klencke BJ. A phase 2 study of PNT2258 in patients with relapsed or refractory (r/r) diffuse large b-cell lymphoma (DLBCL): An initial report from the Wolverine study. *J Clin Oncol* 34:TPS7577, 6/2016.
 38. Issa A, Sathyanarayanan V, Fanale MA, Oki Y, Hagemeister FB, Neelapu SS, Nastoupil LJ, Fowler NH, Turturro F, Noorani M, Ahmed MA, Davis RE, Rodriguez MA, Wang M, Feng L, Young K, McDonnell T, Pinnix CC, Fayad LE, Westin JR. Outcomes of diffuse large b-cell lymphoma with MYC and/or BCL2 protein expression treated with intensive chemotherapy. *J Clin Oncol* 34:7563, 6/2016.
 39. Westin JR, Oki Y, Fayad LE, Nastoupil L, Turturro F, Hagemeister FB, Sathyanarayanan V, Young KH, McDonnell T, Chuang HH, Zhou S, Neelapu SS, Davis RE. Rituximab, lenalidomide, and ibrutinib alone and combined with dose adjusted chemotherapy for patients with high risk diffuse large B-cell lymphoma. *J Clin Oncol* 34:TPS7575, 6/2016.
 40. Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Jacobson CA, Westin JR, Chavez JC, Ghobadi A, Herrera AF, LaCasce AS, Bot A, Rossi JM, Jiang Y, Aycok JS, Elias M, Wiezorek J, Go Wy. A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1. *Blood* (2016 ASH Annual Meeting) 128(26):998, 12/2016.
 41. Simar KA, Sathyanarayanan V, Issa AK, Ahmed MA, Noorani M, Fanale MA, Oki Y, Hagemeister FB, Neelapu SS, Nastoupil LJ, Fowler N, Turturro F, Davis RE, Rodriguez MA, Wang M, Feng L, Young KH, McDonnell TJ, Pinnix CC, Fayad LE, Westin JR. Analyzing Patient Characteristics Who Received (DA) EPOCH-R for High Risk Diffuse Large B-Cell

- Lymphoma: MD Anderson Cancer Center Experience. *Blood* (2016 ASH Annual Meeting) 128(26):4208, 12/2016.
42. Jain P, Kanagal-Shamanna R, San Lucas F, Wang M, Romaguera JE, Fayad LE, Oki Y, Westin JE, Medeiros LJ, Fowler N. Characteristics, Outcome and Pattern of Mutations in Patients with Follicular Lymphoma Who Progressed on BTK Inhibitors (Ibrutinib and acalabrutinib). *Blood* (2016 ASH Annual Meeting) 128(26):2975, 12/2016.
 43. Wang M, Lee HJ, Thirumurthi S, Chuang HH, Hagemeister FB, Westin JR, Fayad LE, Samaniego F, Turturro F, Chen W*, Oriabure O*, Huang SY, Li S, Zhang L, Badillo M, Hartig KH*, Ahmed M, Nomie K, Lam LT, Addison AA, Romaguera JE. Chemotherapy-Free Induction with Ibrutinib-Rituximab Followed By Shortened Cycles of Chemo-Immunotherapy Consolidation in Young, Newly Diagnosed Mantle Cell Lymphoma Patients: A Phase II Clinical Trial. *Blood* (2016 ASH Annual Meeting) 128(26):147, 12/2016.
 44. Scherer F, Kurtz DM, Newman AM, Esfahani MS, Craig A, Stehr H, Lovejoy AF, Chabon JJ, Liu CL, Zhou Li, Glover C, Visser BC*, Poultides G, Advani RH, Maeda LS, Gupta NK, Levy R, Ohgami RS, Davis ER, Gaidano G, Kunder CA, Rossi D, Westin JR, Diehn M, Alizadeh AA. Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma Clinically Relevant Abstract. *Blood* (2016 ASH Annual Meeting) 128(26):1089, 12/2016.
 45. Sathyanarayanan V, Oki Y, Issa AK, Ahmed MA, Noorani M, Fanale MA, Hagemeister FB, Neelapu SS, Nastoupil LJ, Fowler N, Turturro F, Davis ER, Rodriguez AM, Wang M, Feng L, Young KH, McDonnell TJ, Pinnix CC, Fayad LE, Westin JR. High Risk Diffuse Large B Cell Lymphoma: A Comparison of Aggressive Subtypes Treated with Dose Adjusted Chemotherapy—the University of Texas MD Anderson Experience. *Blood* (2016 ASH Annual Meeting) 128(26):106, 12/2016.
 46. Neelapu SS, Locke FL, Bartlett NL, Lekakis L, Miklos D, Jacobson CA, Braunschweig I, Oluwole O, Siddiqi T, Lin Y, Timmerman J, Stiff PJ, Friedberg J, Flinn I, Goy A, Smith M, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Reagan P, Bot A, Rossi JM, Navale L, Jiang Y, Aycock JS, Elias M, Wiezorek J, Go WY. Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 ZUMA-1. *Blood* (2016 ASH Annual Meeting) 128(26):LBA-6, 12/2016.
 47. Havranek O, Xu J, Koehrer S, Wang Z, Comer J, Becker L, Yi AF, Burger JA, Westin JR, Zal T, Davis RE. Molecular Aspects of Tonic B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma Provide Biomarkers and Targets for Specific Inhibition. *Blood* (2016 ASH Annual Meeting) 128(26):779, 12/2016.
 48. Quesada AQ, Desai P, Tang G, Lin P, Westin JR, Seegmiller AC, Yin CC, Wang W, Xu J, Miranda RN, Reddy N, Medeiros LJ, Li S. MYC Copy Number Aberrancies Predict a Worse Prognosis in Patients with Diffuse Large B-Cell Lymphoma. *Blood* (2016 ASH Annual Meeting) 128(26):154, 12/2016.
 49. Kurtz DM, Scherer F, Newman AM, Craig A, Jin M, Stehr H, Chabon JJ, Esfahani M, Liu CL, Zhou L, Glover C, Visser BC, Poultides G, Advani RH, Maeda LS, Gupta NK, Levy R, Ohgami RS, Davis ER, Kunder CA, Westin JR, Diehn M, Alizadeh AA. Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma. *Blood* (2016 ASH Annual Meeting) 128(26):2930, 12/2016.
 50. Hu B, Younes A, Claret L, Feng L, Westin JR, Fowler N, Neelapu SS, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Nastoupil LJ, Copeland AR, Fanale MA, Oki Y. The Final Report of a Phase I/II Study of Panobinostat in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients (pts) with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL). *Blood* (2016 ASH Annual Meeting) 128(26):1833, 12/2016.
 51. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler N, Medeiros LJ, Davis RE, Oki Y. The Risk of Central Nervous System (CNS) Relapses in Patients with Peripheral T-Cell Lymphoma. *Blood* (2016 ASH Annual Meeting) 128(26):4153, 12/2016.

52. Strati P, Oki Y, Fayad LE, Nastoupil L, Fowler N, Hagemeister F, Kwak L, Lee HJ, Wang M, Westin J, Ruben C, Wesson E, Fanale M. A Phase 1 Trial of Alisertib and Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas. *Blood* 130:4074, 12/2017.
53. Jain P, Kanagal-Shamanna R, Ghorab A, Nastoupil L, Fayad LE, Medeiros J, Hu S, Neelapu SS, Westin J, Oki Y, Wang M, Fowler N. Characteristics, Treatments, and Outcomes of Patients with Lymphomatoid Granulomatosis—MD Anderson Cancer Center Experience. *Blood* 130:2852, 12/2017.
54. Kurtz DM, Jin M, Soo J, Scherer F, Craig A, Chabon JJ, Schroers-Martin J, Long Liu C, Stehr R, Schmitz C, Duehrsen U, Hüttmann A, Ségolène Cottreau A, Meignan M, Casasnovas O, Westin J, Gaidano G, Rossi D, Roschewski M, Wilson WH, Diehn M, Alizadeh AA. Circulating Tumor DNA Is a Reliable Measure of Tumor Burden at Diagnosis of Diffuse Large B Cell Lymphoma: An International Reproducibility Study. *Blood* 130:310, 12/2017.
55. Schroers-Martin JG, Kurtz DM, Soo J, Jin M, Scherer F, Craig A, Chabon JJ, Long Liu C, Stehr H, Duehrsen U, Hüttmann A, Ségolène Cottreau A, Meignan M, Casasnovas O, Westin J, Gaidano G, Rossi D, Advani R, Roschewski M, Wilson W, Diehn M, Alizadeh AA. Determinants of Circulating Tumor DNA Levels across Lymphoma Histologic Subtypes. *Blood* 130:4018, 12/2017.
56. David M. Kurtz, Florian Scherer, Michael Jin, Joanne Soo, Alexander Craig, Mohammad S Esfahani, Jacob J Chabon, Henning Stehr, Chih Long Liu, Robert Tibshirani, Lauren S. Maeda, Neel K. Gupta, Michael Khodadoust, Ranjana H. Advani, Ronald Levy, Aaron Newman, Jason R. Westin, Gianluca Gaidano, Davide Rossi, Maximilian Diehn and Ash A. Alizadeh. Development of a Dynamic Model for Personalized Risk Assessment in Large B-Cell Lymphoma. *Blood* 130:826, 12/2017.
57. Chihara D, Fowler N, Oki Y, Fanale M, Nastoupil L, Westin J, Fayad LE, Neelapu SS, Cheah CY. Difference in Survival Outcome of Primary Central Nervous System Lymphoma By Histologic Types. *Blood* 130:4137, 12/2017.
58. Nastoupil L, Westin J, Fowler N, Fanale M, Samaniego F, Oki Y, Dsouza L, Obi C, Cao JJ, Cheng X, MA M, Zhiqiang W, Feng F, Zhou S, Davis RE, Neelapu SS. High Complete Response Rates with Pembrolizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: Results of an Open-Label, Phase II Study. *Blood* 130:414, 12/2017.
59. Westin J, Oki Y, Nastoupil L, Fayad L, Neelapu S, Turturro F, Hagemeister F, Rodriguez MA, Lee HJ, Young K, McDonnell T, Ford RJ, Davis RE. Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase I/II Results. *Blood* 130:189, 12/2017.
60. Richard Thomas Maziarz, Michael R. Bishop, Constantine S. Tam, Peter Borchmann, Ulrich Jaeger, Joseph P. McGuirk, Edmund K. Waller, Samantha Jaglowski, Charalambos Andreadis, Stephen Ronan Foley, Isabelle Fleury, Stephan Mielke, Jason R. Westin, Phoebe Joy Ho, Veronika Bachanova, Harald Holte, John M. Magenau, Oezlem Anak, Lida Bubuteishvili Pacaud, Siegbert Guenther, Jie Zhang, Lawrence Rasouliyan, Feng Tai, Gilles Salles and Stephen J. Schuster. Patient-Reported Quality of Life (QoL) Following CTL019 Infusion in Adult Patients (pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL). *Blood* 130:5215, 12/2017.
61. Frederick L. Locke, Jason R. Westin, David B. Miklos, Alex F. Herrera, Caron A. Jacobson, Jennifer Lee, John M. Rossi, Adrian Bot, Allen Xue, Lynn Navale, Jeff S. Aycock, Jeffrey S. Wieszorek and Zachary J. Roberts. Phase 1 Results from ZUMA-6: Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL). *J Clin Oncol* 130:2826, 12/2017.
62. Stephen J. Schuster, Michael R. Bishop, Constantine S. Tam, Edmund K. Waller, Peter Borchmann, Joseph P. McGuirk, Ulrich Jaeger, Samantha Jaglowski, Charalambos Andreadis, Jason R. Westin, Isabelle Fleury, Veronika Bachanova, Stephen Ronan Foley, P. Joy Ho, Stephan Mielke, John M. Magenau, Harald Holte, Koen Van Besien, Marie Jose Kersten, Takanori Teshima, Kensei Tobinai, Paolo Corradini, Oezlem Anak, Lida Bubuteishvili Pacaud, Christopher del Corral, Rakesh Awasthi, Feng Tai, Gilles Salles and Richard Thomas Maziarz. Primary Analysis of Juliet: A Global, Pivotal, Phase 2 Trial of

- CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *Blood* 130:577, 12/2017.
63. Melody R Becnel, Loretta Nastoupil, R. Eric Davis, F. B. Hagemeister, Michelle A. Fanale, Luis Fayad, Jason R. Westin, Michael Wang, Yasuhiro Oki, Linda Claret, Sheryl G Forbes, Lei Feng, Felipe Samaniego, Sattva S. Neelapu and Nathan Fowler. Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial. *Blood* 130:4040, 12/2017.
 64. Dai Chihara, Yasuhiro Oki, Michelle A. Fanale, Jason R. Westin, Loretta Nastoupil, Sattva S. Neelapu, Luis E. Fayad, Nathan H. Fowler and Chan Yoon Cheah. Stage I Lymphoma: Difference in Survival Outcome By Site of Involvement. *Blood* 130:1569, 12/2017.
 65. Chihara D, Dabaja B, Oki Y, Westin J, Cheah CY, Pinnix C, Neelapu S, Fanale M, Fowler N, Nastoupil L. You have accessThe Role of Radiation Therapy and Risk of Developing Secondary Gastric Cancer in Patients Presenting with Early Stage Gastric Lymphoma. *Blood* 130:1569, 12/2017.
 66. Nathan Hale Fowler, Sattva Swarup Neelapu, Felipe Samaniego, Sheryl Forbes, Fredrick B. Hagemeister, Luis Fayad, Lei Feng, Francesco Turturro, Jason R. Westin, Janine Arafat, Eleanor Neal, Loretta J. Nastoupil. Activity of the immunologic doublet of lenalidomide plus obinutuzumab in relapsed follicular lymphoma: Results of a phase I/II study. *J Clin Oncol* 35, 2017 (suppl; abstr 7531), 2017.
 67. Michael C. Jin, David Matthew Kurtz, Mohammad Shahrokh Esfahani, Florian Scherer, Alexander F.M. Craig, Joanne Soo, Michael Siavash Khodadoust, Ruth Sharon Saganty, Jacob J. Chabon, Joseph Schroers-Martin, Henning Stehr, Ranjana H. Advani, Davide Rossi, Gianluca Gaidano, Jason R. Westin, Maximilian Diehn, Ash A. Alizadeh. Noninvasive detection of clinically relevant copy number alterations in diffuse large B-cell lymphoma. *J Clin Oncol* 35, 2017 (suppl; abstr 7507), 2017.
 68. Hu B, Loghavi S, Fayad LE, Noorani M, Fowler NH, Hagemeister FB, Lee HJ, Nastoupil LJ, Neelapu SS, Fanale MA, Samaniego F, Turturro F, Wang M, Davis RE, Westin JR, Medeiros LJ, Oki Y. Outcomes of De Novo CD5+ Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab (R) Era. *J Clin Oncol* 35, 2017 (suppl; abstr e19019), 2017.
 69. Loretta J. Nastoupil, Jason R. Westin, Nathan Hale Fowler, Michelle A. Fanale, Felipe Samaniego, Yasuhiro Oki, Chizobam Obi, JingJing Cao, Xiaoyun Cheng, Man Chun John Ma, Zhiqiang Wang, Fuliang Chu, Lei Feng, Shouhao Zhou, Richard Eric Davis, Sattva Swarup Neelapu;. Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: Interim results of an on open-label, phase II study. *J Clin Oncol* 35, 2017 (suppl; abstr 7519), 2017.
 70. Neeraj Y Saini, MD, Rima M. Saliba, PhD, Gabriela Rondon, MD, Farzaneh Maadani, Uday Popat, MD, Betul Oran, MD MS, Chitra Hosing, MD, Qaiser Bashir, MD MBBS, Amanda L. Olson, MD, Yago Nieto, MD PhD, Amin M. Alousi, MD, Partow Kebriaei, MD, Samer A. Srour, MD, Rohtesh S. Mehta, MD MPH, MS, Paolo Anderlini, MD, Elizabeth J. Shpall, MD, Muzaffar H. Qazilbash, MD, Issa F. Khouri, Luis E. Fayad, Hun Ju Lee, MD, Nathan H. Fowler, MD, Simrit Parmar, MBBS, Jason R. Westin, MD, F. B. Hagemeister, MD, Richard E Champlin, MD, Stefan O. Ciurea. Allogeneic Transplantation for Lymphoid Malignancies with Fludarabine and Melphalan Conditioning and Different Donor Types. *Blood* 132, 2018.
 71. Loretta J. Nastoupil, MD, Michael D. Jain, MD PhD, Jay Y. Spiegel, MD, Armin Ghobadi, MD, Yi Lin, MD PhD, Saurabh Dahiya, MD, Matthew A. Lunning, DO, Lazaros J. Lekakis, MD, Patrick M. Reagan, MD, Olalekan O. Oluwole, MBBS, MPH, Joseph P. McGuirk, DO, Abhinav Deol, MD, Alison R. Sehgal, MD, Andre Goy, MD, Brian T. Hill, MD PhD, Charalambos Andreadis, MD, Javier Munoz, MD, Jason R. Westin, MD, Julio C. Chavez, MD, Amanda F Cashen, MD, Nora N Bennani, MD, Aaron P. Rapoport, MD, Julie M. Vose, MD MBA, David B. Miklos, MD PhD, Sattva S. Neelapu, MD, Frederick L. Locke, MD. Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience. *Blood* 132, 2018.
 72. Caron A. Jacobson, MD MMSc, Frederick L. Locke, MD, David B. Miklos, MD PhD, Alex F. Herrera, MD, Jason R. Westin, MD, Jennifer Lee, John M. Rossi, MS, Lianqing Zheng, PhD, Mauro P. Avanzi, MD, Zachary J. Roberts, MD, PhD, Jennifer Sun, MS. End of Phase 1

- Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma. *Blood* 132, 2018.
73. Joseph G Schroers-Martin, MD, Andrea Garofalo, Joanne Soo, BS, Michael C. Jin, David M. Kurtz, MDPH, Lieselot Buedts, Ulrich Dühsen, Prof, MD PhD, Andreas Hüttmann, MD, Anne Ségolène Cottereau, Michel Meignan, Olivier Casasnovas, MD, Jason R. Westin, MD, Gianluca Gaidano, MD PhD, Davide Rossi, MD PhD, Mark Roschewski, MD, Wyndham H. Wilson, MD PhD, Ranjana H Advani, MD, Peter Vandenberghe, MD, Maximilian Diehn, MD PhD, Kiran Khush, MD, Ash A. Alizadeh, MD PhD. Lymphoma Virome Dynamics Revealed By Cell-Free DNA Sequencing. *Blood* 132, 2018.
 74. Michael C. Jin, Joseph G Schroers-Martin, MD, David M. Kurtz, MD PhD, Lieselot Buedts, Mohammad S Esfahani, PhD, Charles Macaulay, BS, Brian Swarder, MD PhD, Joanne Soo, BS, Cynthia Glover, Mark Roschewski, MD, Wyndham H. Wilson, MD PhD, Ulrich Dühsen, Prof, MD PhD, Andreas Hüttmann, MD, Davide Rossi, MD PhD, Gianluca Gaidano, MD PhD, Jason R. Westin, MD, Lauren S. Maeda, MD, Ranjana H Advani, MD, Peter Vandenberghe, MD, Maximilian Diehn, MD PhD, Arash A. Alizadeh, MD PhD. Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma. *Blood* 132, 2018.
 75. Preetesh Jain, MBBS,MDDM,PhD, Loretta J. Nastoupil, MD, Rashmi Kanagal-Shamanna, MD, Graciela M. Nogueras González, MPH, Mansoor Noorani, Jorge Enrique Romaguera, Luis Fayad, MD, Felipe Samaniego, MD, Jason R. Westin, MD, L. Jeffrey Medeiros, MD, Sattva Neelapu, Michael Wang, MD, Nathan H. Fowler, MD. Prognostic Factors, Outcomes and Clinical Characteristics in Patients with Transformed Follicular Lymphoma (t-FL): Cohort Study of 172 Patients. *Blood* 132, 2018.
 76. Loretta J. Nastoupil, MD, Hun Ju Lee, MD, F. B. Hagemeister, MD, Jason R. Westin, MD, Felipe Samaniego, MD, Lei Feng, MS, Jiffin John, Sheryl G Forbes, Luis E. Fayad, Michael R Green, PhD, R. Eric Davis, MD, Sattva S. Neelapu, MD, Nathan H. Fowler, MD. Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study. *Blood* 132, 2018.
 77. Dahlia Sano, MBBS, Loretta J. Nastoupil, MD, Nathan H. Fowler, MD, Luis Fayad, MD, F. B. Hagemeister, MD, Hun Ju Lee, MD, Felipe Samaniego, MD, Michael Wang, MD, Maria Alma Rodriguez, MD, Swaminathan P Iyer, MD, Simrit Parmar, MBBS, Raphael Steiner, MD, Ranjit Nair, MBBS,MD, Sherry Adkins, ANP, Sara Arafat, MD, Ahalya Rao, MD, Liliana Vallejo, Misha Hawkins, Yiming Chen, Jason R. Westin, MD, Sattva S. Neelapu, MD. Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma. *Blood* 132, 2018.
 78. Nathan H. Fowler, MD, Preetesh Jain, MBBS,MDDM,PhD, Loretta J. Nastoupil, MD, F. B. Hagemeister, MD, Sheryl G Forbes, Lore Lagrone, Luis Fayad, MD, Hun Ju Lee, MD, R. Eric Davis, MD, Jason R. Westin, MD, Michael Wang, MD, Sattva S. Neelapu, MD, Felipe Samaniego, MD. Seven Year Follow up and Comparison of Dosing Strategies from the Pivotal Phase II Clinical Trial of Lenalidomide Plus Rituximab (R2) in Previously Untreated Follicular Lymphoma. *Blood* 132, 2018.
 79. Stephen J. Schuster, MD, Michael R. Bishop, MD, Constantine Tam, MD PhD, Peter Borchmann, MD, Ulrich Jaeger, MD, Edmund K. Waller, MD, Harald Holte, MD PhD, Joseph P. McGuirk, DO, Samantha Jaglowski, MDMPH, Kensei Tobinai, MD PhD, Charalambos Andreadis, MD MSCE, Isabelle Fleury, Stephan Mielke, MD, Takanori Teshima, Jason R. Westin, MD, Veronika Bachanova, MD PhD, Stephen Ronan Foley, MD FRCPC, P Joy Ho, MBBS(Syd) DPhil(Oxon) FRACP FRCPA FFS(RCPA), John M. Magenau, MD, Nina D. Wagner-Johnston, MD, Koji Kato, MD PhD, Marie Jose Kersten, MD PhD, Koen Van Besien, MD PhD, Jufen Chu, PhD, Aline Jary, MS, Özlem Anak, MD, Gilles Salles, MD PhD, Richard Thomas T. Maziarz, MD. Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel. *Blood* 132, 2018.
 80. Anas Younes, MD, Connie Lee Batlevi, MD PhD, Jonathon B. Cohen, MDMS, Sven de Vos, MD PhD, Daniel J. Landsburg, MD, Zaw Win Myint, MD, Krish Patel, MD, Tycel J. Phillips, MD, Sonali M. Smith, MD, Jason R. Westin, MD, Anna W Ma, MS, Dena Grayson, MD PhD,

- Reinhard von Roemeling, MD, Stefan K. Barta, MD MRCP, MS. A Multi-Center Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Fimepinostat (CUDC-907) in Combination with Venetoclax in Patients with Relapsed/Refractory (R/R) Lymphoma. *Blood* 134, 2019.
81. Nathan H Fowler, MD, Loretta J. Nastoupil, MD MSc, Collin Chin, MBBS, Paolo Strati, MD, Fredrick B. Hagemeister, MD, Luis E. Fayad, MD, Jason R. Westin, MD, Sheryl G Forbes, Janine Arafat, Lei Feng, MS, Ranjit Nair, MBBS,MD, Raphael E Steiner, MD, Felipe Samaniego, MD, Sattva S Neelapu, MD. A Phase I/II Study of Lenalidomide Plus Obinutuzumab in Relapsed Indolent Lymphoma. *Blood* 134, 2019.
 82. Swami P. Iyer, MD, Sattva S Neelapu, MD, Ethan Burns, MD, Ranjit Nair, MBBS,MD, Chitra Hosing, MD, Yago Nieto, MD PhD, Jason R. Westin, MD, Simrit Parmar, MBBS, Nathan H. Fowler, MD, Loretta J. Nastoupil, MD MSc, Madeleine Duvic, MD, Roberto N. Miranda, MD, Hun Ju Lee, Felipe Samaniego, MD, Sairah Ahmed, MD, Feng Lei, MS, Auris Huen, MD. A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL). *Blood* 134, 2019.
 83. Lymphoma: The First-Mind Trial John M Burke, MD, Marc André, Bruce D. Cheson, MD, Johannes Duell, MD, Grzegorz Nowakowski, MD, Andreas Rosenwald, MD, Gilles A. Salles, MD PhD, Jeff P. Sharman, MD, Philipp Bernhard Staber, MD PhD, Marek Trněný, MD, Jason R. Westin, MD, Wolfram Brugger, Günter Fingerle-Rowson, MD PhD, Magdalena Klanova, Guido Würth, PhD, Lorenz Truemper, MD. A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial. *Blood* 134, 2019.
 84. Jason R. Westin, MD, Nathan H. Fowler, MD, Loretta J. Nastoupil, MD MSc, Sattva S Neelapu, MD, Hun Ju Lee, Fredrick B. Hagemeister, MD, Maria Alma Rodriguez, MD, Raphael E Steiner, MD, Sairah Ahmed, MD,. A Phase II Trial of Nivolumab and Ibrutinib for Patients with Relapsed or Refractory Central Nervous System Lymphoma. *Blood* 134, 2019.
 85. Preetesh Jain, MBBS,MDDM,PhD, Rashmi Kanagal-Shamanna, MD, Chi Young Ok, MD, Gonzalez-Pagan Omarya, Lucy Navsaria, MB BCH BAO, Graciela M. Nogueras González, MPH, Shaojun Zhang, PhD, Guangchun Han, Ahmad Ghorab, Prajwal Boddu, MD, F. B. Hagemeister, MD, Hun Ju Lee, MD, Krystle Nomie, PhD, Changying Jiang, PhD, Luis Fayad, MD, Jason R. Westin, MD, Loretta J. Nastoupil, MD MSc, Sairah Ahmed, MD, Swaminathan P. Iyer, MD, Richard E. Champlin, MD, Sattva S Neelapu, MD, Jorge Enrique Romaguera, MD, Nathan H. Fowler, MD, Guilin Tang, MD, Shaoying Li, MD, Keyur Patel, MD PhD, Selvi Thirumurthi, Pan Tinsu, Guofang Xu, MD, Linghua Wang, PhD, Michael L. Wang, MD. Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma - Cohort Study of 369 Patients. *Blood* 134, 2019.
 86. Paolo Strati, MD, Sudhakar Tummala, Loretta J. Nastoupil, MD MSc, Jason R. Westin, MD, Luis Fayad, MD, Sairah Ahmed, MD, Nathan H. Fowler, MD, F. B. Hagemeister, MD, Hun Ju Lee, MD, Swaminathan P. Iyer, MD, Ranjit Nair, MD, Simrit Parmar, MBBS, Maria Alma Rodriguez, MD, Felipe Samaniego, MD, Raphael Eric Steiner, MD, Michael L. Wang, MD, Chelsea Camille Pinnix, MD PhD, Sherry Adkins, ANP, Catherine M. Claussen, MS, Charles Martinez, Misha Hawkins, Nicole Johnson, Shirley George, Sattva S Neelapu, MD, Linda Chi, MD. Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma. *Blood* 134, 2019.
 87. Yingjun Wang, Ken H. Young, MD PhD, Denái R. Milton, Celina Ledesma, Elias Jabbour, MD, Zijun Yidan Xu-Monette, PhD, Jeffrey J. Molldrem, Paolo Anderlini, Amin M. Alousi, MD, Qaiser Bashir, MBBS, May Daher, MD, Luis E. Fayad, MD, Swaminathan P. Iyer, MD, Partow Kebriaei, MD, David Marin, MD, Rohtesh S. Mehta, MD, Amanda L. Olson, MD, Uday Popat, MD, Felipe Samaniego, MD, Jason R. Westin, MD, Muzaffar H. Qazilbash, MD, Jin S Im, MD PhD, Gabriela Rondon, MD, Alison Gulbis, Richard E. Champlin, MD, Issa F. Khouri, MD. Clinical Relevance of MYC/BCL2 and Cell of Origin in Patients with Relapsed Diffuse Large B-Cell Lymphoma Treated with Autologous Stem Cell Transplantation. *Blood* 134, 2019.

88. Ethan Burns, MD, Kartik Anand, MD, Jason R. Westin, MD, Sai Ravi Kiran Pingali, MD, Joe Ensor, PhD, Dahlia Sano, MD, Loretta J. Nastoupil, MD MSc, Hun Ju Lee, Yago Nieto, MD PhD, Issa F. Khouri, MD, Felipe Samaniego, MD, Simrit Parmar, MBBS, Michael Wang, MD, Misha Hawkins, Sherry Adkins, ANP, Luis E. Fayad, MD, Raphael E Steiner, MD, Ranjit Nair, MBBS,MD, Sairah Ahmed, MD, Nathan H. Fowler, MD, Sattva S Neelapu, MD, Swaminathan P. Iyer, MD. Comparative Review of 30 Day Non-Relapse Mortality (NRM) in B-Cell Lymphomas Associated with Anti-CD19 Chimeric Antigen Receptor T-Cells (CAR-T) from FDA Database, Clinical Studies, and MD Anderson. *Blood* 134, 2019.
89. Charalambos Andreadis, MD MSCE, Constantine S. Tam, MBBS, MD, Peter Borchmann, MD PhD, Ulrich Jaeger, MD, Joseph P. McGuirk, DO, Harald Holte, MD PhD, Edmund K. Waller, PhDMD, Samantha Jaglowski, MDMPH, Michael R. Bishop, MD, Stephen Ronan Foley, MD FRCPC, Jason R. Westin, MD, Isabelle Fleury, MD, P Joy Ho, MBBS(Syd) DPhil(Oxon) FRACP FRCPA FFSc(RCPA), Stephan Mielke, MD, Takanori Teshima, MD, Gilles A. Salles, MD PhD, Stephen J Schuster, MD, Veronika Bachanova, MD PhD, Richard T. Maziarz, MD, Koen Van Besien, MD PhD, Koji Izutsu, MD PhD, John M. Magenau, MD, Nina D. Wagner-Johnston, MD, Koji Kato, MD PhD, Paolo Corradini, Ranjan Tiwari, MSc, Rakesh Awasthi, PhD, Tomasz Lawniczek, MD, Lamis K. Eldjerou, MD, Marie Jose Kersten, MD PhD. Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel. *Blood* 134, 2019.
90. Jason R. Westin, MD, Constantine S. Tam, MBBS, MD, Peter Borchmann, MD, Ulrich Jaeger, MD, Joseph P. McGuirk, DO, Harald Holte, MD PhD, Edmund K. Waller, PhDMD, Samantha Jaglowski, MDMPH, Michael R. Bishop, MD, Charalambos Andreadis, MD MSCE, Stephen Ronan Foley, MD FRCPC, Isabelle Fleury, MD, P Joy Ho, MBBS(Syd) DPhil(Oxon) FRACP FRCPA FFSc(RCPA), Stephan Mielke, MD, Takanori Teshima, MD, Stephen J Schuster, MD, Veronika Bachanova, MD PhD, Richard T. Maziarz, MD, Koen Van Besien, MD PhD, Koji Izutsu, MD PhD, Marie Jose Kersten, MD PhD, John M. Magenau, MD, Nina D. Wagner-Johnston, MD, Koji Kato, MD PhD, Paolo Corradini, Xia Han, MS, Ranjan Tiwari, MSc, Sergei Agoulnik, PhD, Lamis K. Eldjerou, MD, Lida Bubuteishvili Pacaud, MD, Gilles A. Salles, MD PhD. Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial. *Blood* 134, 2019.
91. Michael L. Wang, MD, Preetesh Jain, MBBS,MDDM,PhD, Hun Ju Lee, MD, F. B. Hagemeister, MD, Felipe Samaniego, MD, Jason R. Westin, MD, Loretta J. Nastoupil, MD MSc, Wendy Chen, Krystle Nomie, PhD, Shaojun Zhang, PhD, Omar Moghrabi, Shuangtao Zhao, PhD, Rashmi Kanagal-Shamanna, MD, Chi Young Ok, MD, Onyeka Oriabure, Graciela M. Nogueras González, MPH, Dayoung Jung, Lucy Navsaria, MB BCh BAO, Ann Uy, Archie Pedersen, Liang Zhang, MD PhD, Changying Jiang, PhD, Feng Lei, MS, Yixin Yao, PhD, Guofang Xu, MD, Nicolaus Wagner-Bartak, MD, Selvi Thirumurthi, David Santos, Guilin Tang, MD, Keyur Patel, MD PhD, C. Cameron Yin, MD PhD, Michelle Avellaneda, Maria Badillo, Luis Fayad, MD, Sattva S Neelapu, MD, Nathan H. Fowler, MD, Jorge Enrique Romaguera, MD, Linghua Wang, PhD. Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial. *Blood* 134, 2019.
92. Preetesh Jain, MBBS,MDDM,PhD, Hun Ju Lee, MD, Raphael Eric Steiner, MD, F. B. Hagemeister, MD, Felipe Samaniego, MD, Jason R. Westin, MD, Loretta J. Nastoupil, MD MSc, Sairah Ahmed, MD, Swaminathan P. Iyer, MD, Jorge Enrique Romaguera, MD, Shuangtao Zhao, PhD, Krystle Nomie, PhD, Chi Young Ok, MD, Rashmi Kanagal-Shamanna, MD, Onyeka Oriabure, Guofang Xu, MD, Liang Zhang, MD PhD, Changying Jiang, PhD, Dayoung Jung, Lucy Navsaria, MB BCh BAO, Wendy Chen, Omar Moghrabi, Tayyaba Nizam, Chloe Marie McClain, Maria Badillo, Selvi Thirumurthi, David Santos, Guilin Tang, MD, Keyur Patel, MD PhD, Sattva S Neelapu, MD, Linghua Wang, PhD, Nathan H. Fowler, MD, Michael L. Wang, MD. Frontline Treatment with Ibrutinib with Rituximab (IR) Combination Is Highly Effective in Elderly (≥65 years) Patients with Mantle Cell Lymphoma (MCL) - Results from a Phase II Trial. *Blood* 134, 2019.

93. Veronika Bachanova, MD PhD, Constantine S. Tam, MBBS, MD, Peter Borchmann, MD, Ulrich Jaeger, MD, Joseph P. McGuirk, DO, Harald Holte, MD PhD, Edmund K. Waller, PhDMD, Samantha Jaglowski, MDMPH, Michael R. Bishop, MD, Charalambos Andreadis, MD MSCE, Stephen Ronan Foley, MD FRCPC, Jason R. Westin, MD, Isabelle Fleury, MD, P Joy Ho, MBBS(Syd) DPhil(Oxon) FRACP FRCPA FFSc(RCPA), Stephan Mielke, MD, Takanori Teshima, MD, Gilles Salles, MD PhD, Stephen J Schuster, MD, Richard T. Maziarz, MD, Koen Van Besien, MD PhD, Koji Izutsu, MD PhD, Marie Jose Kersten, MD PhD, John M. Magenau, MD, Nina D. Wagner-Johnston, MD, Koji Kato, MD PhD, Paolo Corradini, Jufen Chu, PhD, Irina Gershtgorin, PhD, Therese Choquette, PhD, Lida Bubuteishvili Pacaud, MD, Margit Jeschke, PhD. Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL). *Blood* 134, 2019.
94. Preetesh Jain, MBBS, MDDM, PhD, Shuangtao Zhao, PhD, Rashmi Kanagal-Shamanna, MD, Lucy Navsaria, MB BCh BAO, Holly Hill, Ankita Misra, Krystle Nomie, PhD, Changying Jiang, PhD, Yixin Yao, PhD, Liang Zhang, MD PhD, Loretta J. Nastoupil, MD MSc, F. B. Hagemeister, MD, Jason R. Westin, MD, Ranjit Nair, MD, Raphael Eric Steiner, MD, Onyeka Oriabure, Wendy Chen, Guilin Tang, MD, C. Cameron Yin, MD PhD, Keyur Patel, MD PhD, Jorge Enrique Romaguera, MD, Nathan H. Fowler, MD, Linghua Wang, PhD, Michael L. Wang, MD. Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) - Response and Clinical Outcomes in Ultra-Refractory MCL. *Blood* 134, 2019.
95. Paolo Strati, MD, Ralph J. Johnson, PhD, Sheryl G Forbes, Loretta J. Nastoupil, MD MSc, Felipe Samaniego, MD, Eric Davis, MD, Michael R Green, PhD, Luis Fayad, MD, F. B. Hagemeister, MD, Jason R. Westin, MD, Michael L. Wang, MD, Sattva S Neelapu, MD, Nathan H Fowler, MD. Predictive Factors of Response and Survival of Lenalidomide and Rituximab As Initial Treatment of Follicular Lymphoma. *Blood* 134, 2019.
96. Ian W. Flinn, MD PhD, Jason R. Westin, MD, Jonathon B. Cohen, MDMS, Luke P. Akard, MD, Samantha Jaglowski, MDMPH, Jessica Sachs, MD, Ann Ranger, PhD, Patricia Harris, MPH, Francis Payumo, BSc, MSc, Veronika Bachanova, MD PhD. Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ non-Hodgkin Lymphoma. *Blood* 134, 2019.
97. Chelsea C Pinnix, MD PhD, Jillian R Gunther, MD PhD, Bouthaina S. Dabaja, MD, Sherry Adkins, ANP, Misha Hawkins, Jason R. Westin, MD, Luis Fayad, MD, Sairah Ahmed, MD, Nathan H. Fowler, MD, Fredrick B. Hagemeister, MD, Swaminathan P. Iyer, MD, Maria Alma Rodriguez, MD, Hun Ju Lee, Raphael E Steiner, MD, Ranjit Nair, MBBS, MD, Paolo Strati, MD, Simrit Parmar, MBBS, Felipe Samaniego, MD, Michael Wang, MD, Sattva S Neelapu, MD, Loretta J. Nastoupil, MD MSc. Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma. *Blood* 134, 2019.
98. Loretta J. Nastoupil, MD MSc, Sattva S Neelapu, MD, Eric Davis, MD, Felipe Samaniego, MD, Nathan H Fowler, MD, Jason R. Westin, MD, Hun Ju Lee, Michael Wang, MD, Fredrick B. Hagemeister, MD, Philip Beer, MD PhD, Alexander R. L. Cecil, James Dow, Duncan McHale, Franck Silva, Penny Ward, Arash Yavari, Stephen Joseph Shuttleworth, PhD. Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110 β / δ Inhibitor in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma. *Blood* 134, 2019.
99. Loretta J. Nastoupil, MD MSc, Jason R. Westin, MD, Fredrick B. Hagemeister, MD, Hun Ju Lee, Luis Fayad, MD, Felipe Samaniego, MD, Sairah Ahmed, MD, Linda Claret, Raphael E Steiner, MD, Ranjit Nair, MBBS, MD, Simrit Parmar, MBBS, Maria Alma Rodriguez, MD, Michael L. Wang, MD, Michael R Green, PhD, Eric Davis, MD, Sattva S Neelapu, MD, Nathan H Fowler, MD. Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL). *Blood* 134, 2019.
100. Stefan Alig, MD, Charles Macaulay, MSc, BA, David M. Kurtz, MD PhD, Ulrich Dührsen, Prof, MD PhD, Andreas Hüttmann, MD, Michael C. Jin, BS, Brian Swarder, MD PhD, Andrea Garofalo, BS, BA, Mohammad Shahrokh Esfahani, Joanne Soo, MD, Florian Scherer, MD,

- Alexander Craig, MPhil, Olivier Casasnovas, MD, Jason R. Westin, MD, Gianluca Gaidano, MD PhD, Davide Rossi, MD PhD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD. Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma. *Blood* 1342, 2019.
101. Jason R. Westin, MD, Loretta J. Nastoupil, MD MSc, Luis Fayad, MD, Fredrick B. Hagemeister, MD, Yasuhiro Oki, MD, Francesco Turturro, MD, Sairah Ahmed, MD, Maria Alma Rodriguez, MD, Hun Ju Lee, Raphael Eric Steiner, MD, Ranjit Nair, MBBS, MD, Simrit Parmar, MBBS, Ken H. Young, Timothy J. McDonnell, MD PhD, Hubert Chuang, Michael R Green, PhD, Sattva S Neelapu, MD, Eric Davis, MD. Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase II Results. *Blood* 1342, 2019.
 102. Swami P. Iyer, MD, Jie Xu, MD, Melody R. Becnel, MD, Ranjit Nair, MD, Raphael Steiner, MD, Lei Feng, MS, Hun Ju Lee, MD, Paolo Strati, MD, Sairah Ahmed, MD, Simrit Parmar, MD, MSCI, Yago Nieto, MD, Chitra Hosang, MD, Jason Westin, MD, Loretta J. Nastoupil, MD, Ann Vo, Felipe Samaniego, MD, Nathan H. Fowler, MD, Neeraj Saini, MD, Issa F. Khouri, MD, Jin S. Im, Preetesh Jain, MBBS, MDDM, PhD, Luis Fayad, Michael Wang, MD, Roberto N. Miranda, MD, Francisco Vega, MD PhD, Christopher Flowers, MDMS, Sattva S. Neelapu, MD. A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL). *Blood* 136, 2020.
 103. Paolo Strati, MD, Grace Watson, Sandra B. Horowitz, Pharm.D., Ranjit Nair, MD, Maria Alma Rodriguez, MD, Raphael Eric Steiner, MD, Luis Fayad, Jason R. Westin, MD, Sattva S. Neelapu, MD. Clinical Efficacy of Polatuzumab Vedotin in Patients with Relapsed/Refractory Large B-Cell Lymphoma after Standard of Care Axicabtagene Ciloleucel. *Blood* 136, 2020.
 104. Preetesh Jain, MBBS, MDDM, PhD, Yixin Yao, PhD, Shuangtao Zhao, PhD, Yang Liu, PhD, Holly Hill, Yuxuan Che, Yijing Li, MS, Alexa A Jordan, BS, Joseph McIntosh, BS, Hun Ju Lee, MD, Raphael Eric Steiner, MD, Felipe Samaniego, MD, Jason Westin, MD, Loretta J. Nastoupil, MD, Ranjit Nair, Sairah Ahmed, MD, Chi Young Ok, MD, Rashmi Kanagal-Shamanna, MD, Onyeka Oriabure, Guofang Xu, MD, Wendy Chen, Omar Moghrabi, Chloe Marie McClain, Maria Badillo, MSN, RN, OCN, CCRP, Selvi Thirumurthi, David Santos, Cezar Iliescu, MD, C. Cameron Yin, MD PhD, Shaoying Li, MD, Guilin Tang, MD, Francisco Vega, MD PhD, Sattva S. Neelapu, MD, Christopher Flowers, MDMS, Linghua Wang, PhD, Michael Wang, MD. Combination of Ibrutinib with Rituximab (IR) in Previously Untreated Older Patients with Mantle Cell Lymphoma (MCL) - a Phase II Clinical Trial. *Blood* 136, 2020.
 105. Preetesh Jain, MBBS, MDDM, PhD, Guilin Tang, MD, C. Cameron Yin, MD PhD, Chi Young Ok, MD, Lucy Navsaria, MB BCh BAO, Maria Badillo, MSN, RN, OCN, CCRP, Wendy Chen, Yijing Li, MS, Yuxuan Che, Yang Liu, PhD, Onyeka Oriabure, Graciela M. Noguera Gonzalez, MPH, Jason Westin, MD, Loretta J. Nastoupil, MD, Sairah Ahmed, MD, Ranjit Nair, Selvi Thirumurthi, Shaoying Li, MD, Rashmi Kanagal-Shamanna, MD, Francisco Vega, MD PhD, Christopher Flowers, MDMS, Michael Wang, MD. Complex Karyotype Is a Significant Predictor for Worst Outcomes in Patients with Mantle Cell Lymphoma (MCL) Treated with BTK Inhibitors - Comprehensive Analysis of 396 Patients. *Blood* 136, 2020.
 106. Michael W. Schuster, MD, Miguel A Canales, MD PhD, Jason Westin, MD, José M Zijlstra, MD PhD, George A Follows, MD PhD, Reem Karmali, MDMS, Nagesh Kalakonda, MD, Andre H. Goy, MD, Rene-Olivier Casasnovas, MD, Joost Vermaat, MD PhD, Eric Van Den Neste, MD, Sylvain Choquet, MD, Catherine Thieblemont, MD PhD, Federica Cavallo, MD PhD, Maria de Fatima De La Cruz, MD, Brian T. Hill, MD, Herve Tilly, MD PhD, Shireen Kassam, MBBS, FRCPath, PhD, Reda Bouabdallah, MD, Ulrich Jaeger, MD, Ronit Gurion, MD, Paolo Caimi, MD, Peter Martin, FRCPC, MD MS, Andrew Davies, MD PhD, Sonali M. Smith, MD, Graham P. Collins, MD DPhil, Fritz C. Offner, MD PhD, Gilles Salles, MD PhD, Xiwen Ma, Kelly Corona, Jean-Richard Saint-Martin, Anita A. Joshi, Kamal Chamoun, MD, Hongwei Wang, MD PhD, Jatin J. Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Marie Maerevoet, MD. Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study. *Blood* 136, 2020.
 107. Neeraj Saini, MD, Chia-Chi Chang, PhD, Paolo Strati, MD, Loretta J. Nastoupil, MD, Jason Westin, MD, Ranjit Nair, MD, Luis Fayad, Sairah Ahmed, MD, Hun Ju Lee, MD,

- Swaminathan P Iyer, MD, Raphael Eric Steiner, MD, Uri Greenbaum, MD, Partow Kebriaei, MD, Elizabeth J. Shpall, MD, Nitin Jain, MD, Michael R Green, PhD, Nadim J Ajami, Christopher Flowers, MDMS, Richard E. Champlin, MD, Jennifer Wargo, MD, Sattva S. Neelapu, MD, Robert R. Jenq, MD. Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma. *Blood* 136, 2020.
108. Michael Wang, MD, Preetesh Jain, MBBS,MDDM,PhD, Yixin Yao, PhD, Yang Liu, PhD, Shuangtao Zhao, PhD, Holly Hill, Omar Moghrabi, Hun Ju Lee, MD, Felipe Samaniego, MD, Jason Westin, MD, Loretta J. Nastoupil, MD, Rashmi Kanagal-Shamanna, MD, Chi Young Ok, MD, Wendy Chen, Onyeka Oriabure, Yuxuan Che, Yijing Li, MS, Lei Feng, MS, Graciela M. Nogueras González, MPH, Guofang Xu, MD, Nicolaus Wagner-Bartak, MD, Selvi Thirumurthi, David Santos, Guilin Tang, MD, Francisco Vega, MDPhD, C. Cameron Yin, MD PhD, Michelle Avellaneda, Maria Badillo, MSN, RN, OCN, CCRP, Christopher Flowers, MDMS, Linghua Wang, PhD. Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX in Patients (age $\leq$ 65 years) with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-1 Clinical Trial. *Blood* 136, 2020.
 109. Lauren Willis, PharmD, Tristin Abair, PhD, Pan Chen, PhD, Jason Westin, MD. Innovative, Consequence-Based Educational Intervention Improves Hematologists/Oncologists Skills Using CAR T-Cell Therapies for R/R Diffuse Large B-Cell Lymphoma. *Blood* 136, 2020.
 110. Anita Kumar, MD, Jason Westin, MD, Stephen J Schuster, MD, Grzegorz S. Nowakowski, MD, Izidore S. Lossos, MD, Connie Lee Batlevi, MDPhD, Philip Caron, MD PhD, Pamela Drullinsky, MD, John Gerecitano, MD PhD, Audrey Hamilton, MD, Paul A. Hamlin, MD, Steven M. Horwitz, MD, Allison P. Jacob, Erel Joffe, MD MSc, Ashlee Joseph, Gottfried R. von Keudell, MD PhD, Leana Laraque, BA, Oscar B Lahoud, MD, Matthew J Matasar, MD, Craig H. Moskowitz, MD, Chelsea D Mullins, BS, Ariela Noy, MD, Colette Owens, MD, Maria Lia Palomba, Carol S. Portlock, MD, Ildefonso Rodriguez-Rivera, MD, Gilles Salles, MDPhD, Venkatraman Seshan, PhD, David J. Straus, MD, Shreya Vemuri, Anas Younes, Andrew D Zelenetz, MD PhD. Interim Analysis from a Prospective Multicenter Study of Next-Generation Sequencing Minimal Residual Disease Assessment and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma. *Blood* 136, 2020.
 111. Tycel J. Phillips, MD, Adam J Olszewski, MD, Javier Munoz, MD, Tae Min Kim, MD PhD, Dok Hyun Yoon, Richard Greil, MD, Jason Westin, MD, Ulrich Jaeger, Miguel Canales, Cindy Chen, Betsy Althaus, Carol O'Hear, Raluca Negricea, Yuying Xie, Ronald McCord, Enkhtsetseg Purev, Anusha Vallurupalli. Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma. *Blood* 136, 2020.
 112. Preetesh Jain, MBBS,MDDM,PhD, Shaojun Zhang, PhD, Rashmi Kanagal-Shamanna, MD, Lucy Navsaria, MB BCh BAO, Chi Young Ok, MD, Guilin Tang, MD, C. Cameron Yin, MD PhD, Maria Badillo, MSN, RN, OCN, CCRP, Wendy Chen, Onyeka Oriabure, Hun Ju Lee, MD, Jason Westin, MD, Loretta J. Nastoupil, MD, Omar Moghrabi, Yuxuan Che, Felipe Samaniego, MD, Sairah Ahmed, MD, Ranjit Nair, Shaoying Li, MD, Francisco Vega, MDPhD, Christopher Flowers, MDMS, Linghua Wang, PhD, Michael Wang, MD. Outcomes of Acalabrutinib Failures in Relapsed Mantle Cell Lymphoma. *Blood* 136, 2020.
 113. Hua-Jay J Cherng, MD, Raphael E Steiner, MD, Luis Fayad, Paolo Strati, MD, Ranjit Nair, MD, F. B. B. Hagemeister, MD, Loretta J. Nastoupil, MD, Hun Ju Lee, MD, Sattva S. Neelapu, MD, Christopher Flowers, MDMS, Felipe Samaniego, MD, Maria Alma Rodriguez, MD, Lei Feng, MS, Hubert Chuang, MDPhD, Jason R. Westin, MD. Persistent Overall Response on Early PET/CT Scans during Salvage Therapy for Relapsed or Refractory DLBCL Predicts for Disease Specific Survival. *Blood* 136, 2020.
 114. Paolo Strati, MD, Haleigh Mistry, Brittany Pulsifer, Luis Fayad, Sairah Ahmed, MD, Hun Ju Lee, MD, Swami P. Iyer, MD, Ranjit Nair, MD, Loretta J. Nastoupil, MD, Simrit Parmar, MD, MSCI, Maria Alma Rodriguez, MD, Felipe Samaniego, MD, Raphael Eric Steiner, MD, Michael Wang, MD, Chelsea C. Pinnix, MD PhD, Bouthaina S. Dabaja, MD, Mansoor Noorani, Catherine M. Claussen, MS, Elizabeth J. Shpall, MD, Partow Kebriaei, MD, Chris R. Flowers, MD MS, Jason R. Westin, MD, Sattva S. Neelapu, MD. Prognostic Value of Delta Lymphocyte Index (DLI_x) in Patients with Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy. *Blood* 136, 2020.

115. Samer A. Srour, MD MS, Jie Xu, MD, Taha Al-Juhaishi, MD, Raphael Eric Steiner, MD, Joe Ensor, PhD, Sairah Ahmed, MD, Simrit Parmar, MD, MSCI, Paolo Strati, MD, Loretta J. Nastoupil, MD, Yago Nieto, MD, Chitra Hosing, MD, Hun Ju Lee, MD, Jason Westin, MD, Nathan H. Fowler, MD, Luis Fayad, Bouthaina S. Dabaja, MD, Chelsea C. Pinnix, MD PhD, Jillian R. Gunther, MD PhD, Penny Fang, MD, Felipe Samaniego, MD, Preetesh Jain, MBBS, MDDM, PhD, Richard E. Champlin, MD, Issa F. Khouri, MD, Michael Wang, MD, Roberto N. Miranda, MD, Francisco Vega, MD PhD, Sattva S. Neelapu, MD, Christopher Flowers, MDMS, Swami P. Iyer, MD. Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center. *Blood* 136, 2020.
116. Michael W. Schuster, MD, Miguel A Canales, MD PhD, Jason Westin, MD, Josée M Zijlstra, MD PhD, George A Follows, MD PhD, Reem Karmali, MDMS, Nagesh Kalakonda, MD, Andre H. Goy, MD, Rene-Olivier Casasnovas, MD, Joost Vermaat, MD PhD, Eric Van Den Neste, MD, Sylvain Choquet, MD, Catherine Thieblemont, MD PhD, Federica Cavallo, MD PhD, Maria de Fatima De La Cruz, MD, Brian T. Hill, MD, Herve Tilly, MD PhD, Shireen Kassam, MBBS, FRCPath, PhD, Reda Bouabdallah, MD, Ulrich Jaeger, MD, Ronit Gurion, MD, Paolo Caimi, MD, Peter Martin, FRCPC, MD MS, Andrew Davies, MD PhD, Sonali M. Smith, MD, Graham P. Collins, MD DPhil, Fritz C. Offner, MD PhD, Gilles Salles, MD PhD, Xiwen Ma, Kelly Corona, Jean-Richard Saint-Martin, Anita A. Joshi, Kamal Chamoun, MD, Hongwei Wang, MD PhD, Jatin J. Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Marie Maerevoet, MD. Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study. *Blood* 136, 2020.
117. Uri Greenbaum, MD, Paolo Strati, MD, Rima M. Saliba, PhD, Janet Torres, Gabriela Rondon, Yago Nieto, MD, Chitra Hosing, MD, Samer A. Srour, MD MS, Jason Westin, MD, Luis Fayad, Hun Ju Lee, MD, Swaminathan P Iyer, MD, Loretta J. Nastoupil, MD, Simrit Parmar, MD, MSCI, Maria Alma Rodriguez, MD, Felipe Samaniego, MD, Raphael Eric Steiner, MD, Michael Wang, MD, Chelsea C. Pinnix, MD PhD, Christopher Flowers, MDMS, Sudhakar Tummala, MD, Jeremy Ramdial, MD, Fevzi F. Yalniz, Misha Hawkins, Katayoun Rezvani, MD PhD, Richard E. Champlin, MD, Elizabeth J. Shpall, MD, Sattva S. Neelapu, MD, Partow Kebriaei, MD, Sairah Ahmed, MD. The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL). *Blood* 136, 2020.
118. Paolo Strati, MD, Felipe Samaniego, MD, Mariana Gallardo, Mansoor Noorani, F. B. B. Hagemeister, MD, Jason R. Westin, MD, Hun Ju Lee, MD, Maria Alma Rodriguez, MD, Sattva S. Neelapu, MD, Jillian R. Gunther, MD PhD, Rashmi Kanagal-Shamanna, MD, Francisco Vega, MD PhD, Nathan H Fowler, MD, Chris R. Flowers, MD MS, Loretta J. Nastoupil, MD. Treatment and Outcome of Patients with Follicular Lymphoma Relapsed or Progressed after Frontline Lenalidomide and Rituximab. *Blood* 136, 2020.
119. Sushanth Gouni, MD, Paolo Strati, MD, Jason Westin, MD, Loretta J. Nastoupil, MD, Raphael E Steiner, MD, Ranjit Nair, MD, Luis Fayad, Sattva S. Neelapu, MD, Ralf Landgraf, PhD, Daniel Bilbao, PhD, Francisco Vega, MD PhD, Nitin Agarwal, PhD. Use of Medium Potency Statins Is Associated with Improved Outcomes after Frontline RCHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL). *Blood* 136, 2020.
120. Anita Kumar, Jason R. Westin, Stephen J. Schuster, Grzegorz S. Nowakowski, Izidore S. Lossos, Devin Copley, Clare Grieve, Allison P. Jacob, Ashlee Joseph, Leana Laraque, Gita Masand, Chelsea D Mullins, Ellen Napier, Tania Rodriguez, Venkatraman Seshan, Shreya Vemuri, Andrew D. Zelenetz. A Prospective Multicenter Study of Minimal Residual Disease Assessment Using a Next-Generation Immunosequencing Assay and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma. *Blood* 138, 2021.
121. Hua-Jay J. Cherng, Ryan Sun, Haopeng Yang, Qing Deng, Luis Fayad, Nathan H. Fowler, Simrit Parmar, Sairah Ahmed, Raphael E Steiner, Fredrick B. Hagemeister, Hun Ju Lee, Ranjit Nair, Maria Alma Rodriguez, Felipe Samaniego, Swaminathan P Iyer, Loretta Nastoupil, Sattva S. Neelapu, Paolo Strati, Jason R. Westin, Michael R Green. A Risk Score Incorporating Low Pass Whole Genome Sequencing of Cell Free DNA from Patients Receiving CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma. *Blood* 138, 2021.

122. Ajlan Al Zaki, Jason R. Westin, Grace Watson, Lei Feng, Sairah Ahmed, Haleigh Mistry, Loretta Nastoupil, Misha Hawkins, Ranjit Nair, Swaminathan P Iyer, Hun Lee, Raphael E Steiner, Christopher R. Flowers, Elizabeth J. Shpall, Partow Kebriaei, Sattva S. Neelapu, Paolo Strati. Analysis of Factors Associated with Conversion to CR in Patients with Large B-Cell Lymphoma Achieving Day 30 PR after CAR T-Cell Therapy. *Blood* 138, 2021.
123. Sushanth Gouni, Jason R. Westin, Haleigh Mistry, Raphael Eric Steiner, Jinsu James, Simrit Parmar, Mansoor Noorani, Nathan H. Fowler, Sandra B. Horowitz, Lei Feng, Luis E. Fayad, Swaminathan P Iyer, Michael R Green, Misha Hawkins, Christopher R. Flowers, Sairah Ahmed, Loretta Nastoupil, Sattva S. Neelapu, Yago Nieto, Paolo Strati. Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma Patients in Complete Metabolic Response at Time of Infusion. *Blood* 138, 2021.
124. Jay Y. Spiegel, Michael D. Jain, Loretta Nastoupil, John Tamaresis, Armin Ghobadi, Yi Lin, Lazaros J. Lekakis, Patrick M. Reagan, Olalekan O. Oluwole, Joseph P. McGuirk, Abhinav Deol, Alison R. Sehgal, Andre H. Goy, Brian T. Hill, Charalambos Andreadis, Javier Muñoz, Matthew L. Ulrickson, Jason R. Westin, Julio C. Chavez, Miriam T. Jacobs, N Nora Bennani, Aaron P. Rapoport, Julie M. Vose, David B. Miklos, Sattva S. Neelapu, Frederick L. Locke, Saurabh Dahiya, Matthew A. Lunning. Long-Term Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium. *Blood* 138, 2021.
125. Ranjit Nair, Nafis Deen, Sairah Ahmed, Roberto N. Miranda, Nathan H. Fowler, Luis Fayad, Raphael E Steiner, Fredrick B. Hagemeister, Maria Alma Rodriguez, Hun Ju Lee, Paolo Strati, Luis Malpica-Castillo, Dai Chihara, Preetesh Jain, Jillian R. Gunther, Christopher R. Flowers, L. Jeffrey Medeiros, Yago Nieto, Jeremy L. Ramdial, Sattva S. Neelapu, Loretta Nastoupil, Michael R Green, Michael Wang, Francisco Vega, Lei Feng, Swaminathan Padmanabhan Iyer, Jason R. Westin. Outcome of Patients with T- Cell Histiocyte Rich B Cell Lymphoma: Single Institution Series. *Blood* 138, 2021.
126. Raphael E Steiner, Paolo Strati, Christopher R. Flowers, Sattva S. Neelapu, Michael R Green, Loretta Nastoupil, Fredrick B. Hagemeister, Lei Feng, Sairah Ahmed, Ranjit Nair, Luis Fayad, Hun Ju Lee, Maria Alma Rodriguez, Jason R. Westin. Pacific: A Phase II Study of Brentuximab Vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-Cell Lymphoma. *Blood* 138, 2021.
127. Chelsea C. Pinnix, Bouthaina S. Dabaja, Jillian R. Gunther, Penny Fang, Susan Wu, Loretta Nastoupil, Paolo Strati, Ranjit Nair, Sairah Ahmed, Raphael E Steiner, Luis Malpica-Castillo, Dai Chihara, Preetesh Jain, Luis Fayad, Jason R. Westin, Sattva S. Neelapu, Maria Alma Rodriguez, Fredrick B. Hagemeister, Hun Ju Lee, Michael Wang, Felipe Samaniego, Nathan H. Fowler, Christopher R. Flowers, Lei Feng, Linda Chi, Bitá Esmaeli. Phase II Trial of Response Adapted Ultra Low Dose (ULD) Orbital Radiation Therapy for Indolent B Cell Lymphoma. *Blood* 138, 2021.
128. David M. Kurtz, Jacob J. Chabon, Joanne Soo, Lyron Co Ting Keh, Stefan Alig, Andre Schultz, Michael C. Jin, Florian Scherer, Alexander F. Craig, Chih Long Liu, Ulrich Duehrsen, Andreas Huettmann, René-Olivier Casasnovas, Jason Westin, Mark J. Roschewski, Wyndham H. Wilson, Gianluca Gaidano, Davide Rossi, Maximilian Diehn, Ash A. Alizadeh. Phased variants improve DLBCL minimal residual disease detection at the end of therapy. *Journal of Clinical Oncology* 39, 2021.
129. Frederick L. Locke, MD1, David B. Miklos, MD, PhD2, Caron Jacobson, MD3, Miguel-Angel Perales, MD4, Marie José Kersten, MD, PhD5, Olalekan O. Oluwole, MBBS, MPH6, Armin Ghobadi, MD7*, Aaron P. Rapoport, MD8, Joseph P. McGuirk, DO9, John M. Pagel, MD, PhD10, Javier Muñoz, MD, MS, MBA, FACP11*, Umar Farooq, MD12, Tom Van Meerten, MD, PhD13*, Patrick M. Reagan, MD14, Anna Sureda15, Ian W. Flinn, MD, PhD16, Peter Vandenbergh, MD, PhD17, Kevin Song, MD, FRCPC18, Michael Dickinson, MBBS19, Monique C. Minnema, MD20, Peter A. Riedell, MD21, Lori A. Leslie, MD22*, Sridhar Chaganti, MD23*, Yin Yang, MS, MD24*, Simone Filosto, PhD24*, Marco Schupp, MD24*, Christina To, MD24*, Paul Cheng, MD, PhD24, Leo I. Gordon, MD25 and Jason R. Westin, MD26. Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel

- (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma. *Blood* 138, 2021.
130. Jason R. Westin, Raphael Steiner, Lei Feng, Paolo Strati, Christopher R. Flowers, Sattva S. Neelapu, Loretta Nastoupil, Dai Chihara, Fredrick B. Hagemeister, Sairah Ahmed, Ranjit Nair, Luis Fayad, Hun Ju Lee, Maria Alma Rodriguez, Eric Davis, Michael R Green. Smart Stop: A Phase II Study of Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Chemotherapy in Patients with Newly Diagnosed DLBCL. *Blood* 138, 2021.
 131. Dai Chihara, Loretta Nastoupil, Paolo Strati, Felipe Samaniego, Lei Feng, Maria Alma Rodriguez, Luis Fayad, Jason R. Westin, Fredrick B. Hagemeister, Michael Wang, Sattva S. Neelapu, Nathan H. Fowler. Ten Year Follow up of the MD Anderson Cancer Center Phase 2 Study of Rituximab in Combination with Lenalidomide (R2) for Patients with Low Tumor Burden Follicular Lymphoma. *Blood* 138, 2021.

Book Chapters

1. Westin J, Hagemeister R, Fanale M. "Hodgkin Lymphoma". In: The MD Anderson Manual of Medical Oncology. Second edition, 2009.
2. Westin J, Romaguera J. "Multidisciplinary Approach to Cancer: A Medical Oncologists View." In: *Oncologic Imaging for the Practicing Radiologist, Medical Oncologist and Surgeon*, 2010.
3. Westin J, Kantarjian H, Kurzrock R. "Treatment of Chronic Myelogenous Leukemia as a Paradigm for Solid Tumors: How Targeted Agents in Newly Diagnosed Disease Transformed Outcomes". In: 2012 ASCO Educational Book, ASCO Annual Meeting, 2012.
4. Liu, X, Westin J. "Targeted Therapy of Lymphomas". In: *Handbook of Targeted Cancer Therapy*, 1st. Ed(s) Karp D, Flahook G. Lippincott Williams & Wilkins, 2014. PMID: 9781451193268.
5. Westin JR, Konoplev SN, Fayad LE, Medeiros LJ. Chapter 8: Aggressive B-Cell Lymphomas. In: *The MD Anderson Manual of Medical Oncology*, Third Edition, 3rd. McGraw-Hill: New York, 2016.
6. Nair R, Westin JR. CAR T cells. In: *Advances in Experimental Medicine and Biology*. 1244. Springer, 215-233, 2020.
7. Nair R, Westin J. CAR T cells. In: *Adv Exp Med Biol*. 1244. Springer, 215-233, 2021. PMID: 34972970.
8. Westin, JR. "Multidisciplinary Approach to Cancer: A Medical Oncologists View." In: *Oncologic Imaging: A Multidisciplinary Approach*, 2nd Edition. Elsevier, 2022.
9. Steiner R, Westin JR. Chapter 8: Aggressive B-Cell Lymphomas. In: *The MD Anderson Manual of Medical Oncology*, Fourth Edition, 2022.

Books (edited and written)

N/A

Letters to the Editor

1. Thompson MA, Westin JR, Hagemeister FB. Bone mineral density screening should be routine in lymphoma patients. *Ann Oncol* 25(4):913-4, 4/2014. PMID: 24667725.
2. Westin J, Oki Y, Fayad L. Could treatment with R-HCVAD/R-MA as compared to R- CHOP truly result in improved outcomes for patients with high-risk diffuse large B cell lymphoma? - Response to Landsburg et al. *Br J Haematol* 165(1):146-7, 4/2014. e-Pub 12/2013. PMID: 24329994.
3. Thompson MA, Westin JR, Hagemeister FB. BMD Screening should be routine in lymphoma- Response to Paccou et al. *Annals of Oncology*, 2014.

Manuals, Teaching Aids, Other Teaching Publications

N/A

Other Publications

N/A

EDITORIAL AND REVIEW ACTIVITIES

Editor/Service on Editorial Board(s)

N/A

Member of Editorial Review Board

Associate Editor, American Journal of Blood Research, 2012

Journal Reviewer

Journal Reviewer, Journal of Clinical Oncology, 2015-present

Journal Reviewer, Blood, 2016-present

Journal Review, Cancer, 2016-present

Reviewer, Clinical Lymphoma, Myeloma and Leukemia, 2018-present

Reviewer, JCO Clinical Cancer Informatics, 2018-present

Reviewer, New England Journal of Medicine, 2018-present

Journal Reviewer, Blood Advances, 2019-present

Journal Reviewer, Blood Cancer Journal, Nature, 2019-present

Reviewer, Clinical Cancer Research, 2021-present

Reviewer, Hematologica, 2021-present

Other Editorial and Review Activities

N/A

TEACHING

Teaching Within Current Institution -

Formal Teaching

Courses Taught

N/A

Training Programs

N/A

Other Formal Teaching

N/A

Supervisory Teaching

Committees

Advisory Committees

N/A

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

N/A

Medical Students

N/A

Graduate Students

N/A

Postdoctoral Research Fellows

N/A

Clinical Residents and Fellows

N/A

Other Supervisory Teaching

N/A

Teaching Outside Current Institution

Formal Teaching

Courses Taught

Instructor, Introduction to Clinical Medicine II, University of North Carolina School of Medicine, Course Hours: 6
1/2006-4/2006

Training Programs

Instructor, Internal Medicine Residency, University of North Carolina School of Medicine
6/2005-6/2006

Other Formal Teaching

N/A

Supervisory Teaching

Committees

Advisory Committees

N/A

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

N/A

Medical Students

N/A

Graduate Students

N/A

Postdoctoral Research Fellows

N/A

Clinical Residents and Fellows

N/A

Other Supervisory Teaching

N/A

CONFERENCES AND SYMPOSIA

Organization of Conferences/Symposia (Include chairing session)

ASCO, Chicago, IL, Moderator, 2014

American Society of Hematology, Moderator, 2016

Lymphoma Hub Steering Committee Meeting 2016, Madrid, Spain, Moderator, 5/2016

American Society of Hematology, ASH Meeting on Lymphoma Biology, Colorado Springs, CO, Moderator, 6/2016

ASCO, Chicago, IL, Moderator, 6/2016

American Society of Hematology, San Diego, CA, Moderator, 12/2016

ASCO, Chicago, IL, Moderator, 6/2017

ASH, Atlanta, GA, Keynote Speaker, 12/2017

ASCO 2018, Chicago, IL, Keynote Speaker, 6/2018

Kite National Advisory Board, Scimendum, Chicago, IL, Moderator, 8/2018

Juno Advisory Board, Dava, Dallas, TX, Moderator, 10/2018

Ash 2018, San Diego, CA, Keynote Speaker, 12/2018
Seattle Cancer Center Alliance, Seattle, WA, Keynote Speaker, 2/2019
ASCO, Chicago, IL, Keynote Speaker, 6/2019
ASH, Orlando, FL, Keynote Speaker, 12/2019
ASCO, Chicago, IL, Chair, 6/2022
ASH, New Orleans, LA, Keynote Speaker, 12/2022
ASCO, Chicago, IL, Chair, 6/2023
Genentech NHL Leadership Council, Genentech, Houston, TX, Keynote Speaker, 8/2023

Presentations at National or International Conferences

Invited

Westin, J. "Heat Shock Protein Inhibitor AUY922 in Lymphoma: A Clinical Trial Proposal," American Society of Hematology CTRI, 2012

Westin J. "Phase II Safety and Efficacy Study of CT-011, a Humanized anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma," American Society of Hematology Annual Meeting, Atlanta, GA, 12/10/2012

Westin, JR. "Updated Final Results of Phase II Safety and Efficacy Study of CT-011, a Humanized anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma," Fondazione per la ricerca e la cura dei linfomi, 12th International Conference on Malignant Lymphoma, Lugano, Switzerland, 6/20/2013

Westin, JR. "Phase 0 Trial Design Considerations," American College of Clinical Pharmacology, Bethesda, MD, 9/23/2013

Westin J. "Peripheral T-Cell Lymphoma, Clinical Variability and Optimal Therapy," Malignant Lymphoma Academy, Tokyo, Japan, 2014

Westin J. "Combinations are Critical to Cure Lymphomas: Why and When?," Malignant Lymphoma Academy, Tokyo, Japan, 6/2014

Westin J. "Hodgkin Lymphoma: Can We Move Beyond ABVD?," Malignant Lymphoma Academy, Tokyo, Japan, 6/2014

Xu J, David RE, Wang Z, Westin JR. "Selinexor (KPT-330) is Not Cross-Resistant with Chemotherapy and Demonstrates Strong Synergy with Targeted Therapy in DLBCL," 56th ASH Annual Meeting and Exposition, San Francisco, CA, 12/8/2014

Westin J. "Novel Targeted Therapies in T-cell Lymphoma" at 6th International Hematologic Malignancies Conference, Asia-Pacific Hematology Consortium, Beijing, China, 2/1/2015

Westin J. "High Risk Lymphoma" at the BTH2015 Satellite Symposium, Asia-Pacific Hematology Consortium, Bangkok, Thailand, 2/2/2015

Westin JR. Aggressive Lymphomas: State of the Art Treatment, Mayo Clinic, 26th Annual Hematology Oncology Review, Amelia Island, FL, 7/2016

Westin JR. Aggressive NHLs, Roche Group, Chugai Pharmaceutical, Tokyo, Japan, 8/2016

Westin, JR. Redefining B Cell Malignancies, Janssen, HOLA Dissemination Meeting, Lima, Peru, 9/2016

Westin J. How Best to Manage Patients with Relapsed Mantle Cell Lymphoma, University of Chicago, 14th International Ullmann Chicago Lymphoma Symposium, Chicago, IL, 5/5/2017

Westin J. Non-Hodgkins Lymphoma, Houston, TX, 11/1/2017

Westin J. Car-T cells in NHL, 29th Congress of the Hellenic Society of Haematology, Hellenic Society of Haematology, Thessaloniki, Greece, 11/1/2018

Westin J. Clinical Case Discussion for DLBCL, Foundation for the Institute of Oncology Research, Lugano, Switzerland, 6/2019

Westin J. Best of Lugano, Mumbai Hematology Group, Mumbai, India, 8/2019

Westin J. Evolution of the DLBCL treatment landscape, Abbvie, Lisbon, Portugal, 10/1/2019

Westin JR. Expanding Indications for CARTs: Brexucabtagene Autoleucel for Mantle Cell Lymphoma, ASCO Annual Meeting, 2021

Innovative Approaches in Untreated DLBCL, Society of Hematology Oncology, 2021

Westin J. What's New in CAR-T Therapy?, Scripps, Scripps Conference Service, San Diego, CA, 2/12/2022

Westin J. CAR-T plus X - do we need novel bridging and combination approaches for high-risk patients?, Hartley Taylor Medical Communications, UK Cellular Therapy Forum, Oxford, United Kingdom, 2/28/2022

Westin J. Targeted Oncology Case based Roundtable Meeting on B-cell Lymphoma, MH Life Sciences, MH Life Sciences Event, Houston, TX, 5/9/2022

Primary Refractory Diffuse Large B-cell Lymphoma, Pan Pacific Lymphoma Conference, 7/19/2022

Westin J. A Phase 2, Open-Label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9), SOHO, SOHO, Houston, TX, 9/28/2022

Other, Including Scientific Exhibitions

Westin J. "Lymphoma" at 6th International Hematologic Malignancies Conference, Asian-Pacific Hematology Consortium, Beijing, China, 2/1/2015

Westin J. "Romidepsin" at the 6th International Hematologic Malignancies Conference, Asia-Pacific Hematology Consortium, Beijing, China, 2/1/2015

Westin JR. Genentech National Advisory Board Meeting, Genentech, New York, NY, 9/29/2016

Westin JR, Oki Y, Fayad L, Nastoupil LJ, Turturro F, Hagemeister FB, Sathyanarayanan V, Young KH, McDonnell T, Chuang H, Zhou S, Neelapu SS, David RE. Rituximab, lenalidomide, and ibrutinib alone and combined with dose adjusted chemotherapy for patients, ASCO, Alexandria, VA, 10/18/2016

Westin J. Advisory Board on Tazemetostat in Lymphoma, Dava Oncology, Advisory Board on Tazemetostat in Lymphoma, New York, NY, 2/3/2017

Westin J. Extranodal Presentation of Lymphoma, Scripps, Scripps Conference Services, San Diego, CA, 2/17/2019

Westin J. Car-T cells in NHL, Dava, DAVA Oncology, Whistler, Canada, 3/13/2019

Westin J. Car-T Follow Up, Kite, Milan, Italy, 9/17/2019

Cell Therapy Is the Future, But How Far Will the Car Go?, Scripps MD Anderson, 2021

Utilization of X Plus R-CHOP in High Grade B-cell Lymphomas, Pan Pacific Lymphoma Conference, 2021

Westin J. ZUMA-23: A Global, Phase 3, Randomized Controlled Study of Axicabtagene Ciloleucel vs Standard of Care as First-Line Therapy in Patients With High-Risk Large B-Cell Lymphoma, ICML, Lugano, Switzerland, 6/14/2023

Seminar Invitations from Other Institutions

"Oncologic Emergencies," University of Texas Medical School, Houston, TX, 2/2011

"Heat Shock Protein Inhibitor AUY922 in Lymphoma: A Clinical Trial Proposal," American Society of Hematology Clinical Research Training Institute, Houston, TX, 8/2011

"Update of DLBCL," 2nd Annual Symposium on Current Strategies in the Treatment of Multiple Myeloma, Lymphoma and Leukemia, Houston, TX, 7/2013

"Update of DLBCL," 3rd Annual Symposium on Current Strategies in the Treatment of Multiple Myeloma and Leukemia, Houston, TX, 7/2014

DLBCL 2020 and beyond, AMGEN, AMGEN, Los Angeles, CA, 1/29/2020

CAR-19 T-Cell Therapy for Early Relapse of Large B-cell Lymphoma: Recent Trials and Future Directions, National Cancer Institute, Center for Cancer Research, 1/24/2022

2022 ASH Review, Sarah Cannon Cancer Institute, 4/8/2022

Lectureships and Visiting Professorships

2018 National Advisory Board, 2018 National Advisory Board, Kite Pharma, Chicago, IL, 8/31/2018

DLBCL Center of Excellence Advisory Board, DLBCL Center of Excellence Advisory Board, Juno Pharma, Dallas, TX, 10/13/2018

Smart Start Trial for DLCL, Bedside Bench Conference, NIH, Washington, DC, 10/21/2019

Follow Up for DLBCL, MorphoSys, Boston, MA, 11/6/2019

Other Presentations at State and Local Conferences

Westin J. "Graft versus Host Disease," Citywide Hematology Conference, Houston, TX, 6/2009

Westin, JR. "Is Phase 0 a Hero: Evaluating the Negative Predictive Value of the Phase 0 Trial Concept," Grand Rounds, MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics, Houston, TX, 2/2010

Westin, JR. "Scale Free Networks and Biologic Robustness," Grand Rounds, MD Anderson Cancer Center Department of Investigational Cancer Therapeutics, Houston, TX, 9/2010

"Treatment of Large Cell Lymphoma: Paradigm for Combination Therapy:", Hong's Case Conference, M.D. Anderson Cancer Center, Houston, TX, 1/25/2011

Westin, JR. "It's about Time: Targeted Therapy, CML Blast Crisis, and the Future of Oncology," Grand Rounds, M.D. Anderson Cancer Center Department of Investigational Cancer Therapeutics, Houston, TX, 7/20/2011

Westin, JR. "Update on Lymphomas," "Ask the Doctor" Series, Lymphoma Research Foundation, "Ask the Doctor" Series, Dallas, TX, 1/2013

Westin, JR. "Overview of Treatment Option and role of Novel Therapies in the Management of Aggressive NHLs including MCL," 2nd Annual Symposium on Current Strategies in the Treatment of Multiple Myeloma, Lymphoma and Leukemia, A. Webb Roberts Center for CME of Baylor Health Care System, CancerNet and American Health Resource, Inc, CancerNet, Houston, TX, 7/2013

Westin J. "Can We Move Beyond R-CHOP in DLBCL?," Institutional Grand Rounds, M.D. Anderson Cancer Center, Houston, TX, 2014

Westin J. "Update on Lymphomas," "Ask the Doctor" Series, Lymphoma Research Foundation, Houston, TX, 5/2014

Westin J. "Twitter: Why and How," Writing Week: Twitter and Social Media, M.D. Anderson, Faculty and Academic Development, Houston, TX, 10/24/2014

Westin J. "Diffuse Large B Cell Lymphoma," Baylor College of Medicine Oncology Fellows, M.D. Anderson Cancer Center, Radiation Oncology Department, Houston, TX, 12/2/2014

Westin JR. A Paradigm Shift: The B-Cell Receptor in GCB Diffuse Large B-Cell Lymphoma is Essential and Targetable, Institutional Grand Rounds, M.D. Anderson Cancer Center, Houston, TX, 3/27/2015

Westin J. Diffuse Large B-Cell Lymphoma, Baylor College of Medicine Oncology Fellows, Baylor College of Medicine, Medicine Oncology, Houston, TX, 11/16/2015

Westin JR. DLBCL: Therapeutic Landscape In 2016 and Beyond, Emil J Freireich Grand Rounds, MD Anderson Cancer Center, Lymphoma, Houston, TX, 6/29/2016

Westin, JR. Novel Antibodies, Society of Hematologic Oncology, Society of Hematologic Oncology, Lymphoma, Houston, TX, 9/2016

Westin JR. DLBCL Trial Updates from ASH 2016, Emil J Freireich Grand Rounds, MD Anderson Cancer Center, Lymphoma, Houston, TX, 12/28/2016

Westin J. Non Hodgkins Lymphoma, XXVIII IACRLRD Symposium, MD Anderson Cancer Center, Leukemia, Houston, TX, 11/1/2017

Westin J. Car-T Cell, L/M Patient Conference, MD Anderson Cancer Center, CME Conference Management, San Antonio, TX, 2/2/2019

Westin J. Lymphoma, Medical Oncology and Hematology 2019, MD Anderson Cancer Center, Houston, TX, 2/15/2019

PROFESSIONAL MEMBERSHIPS/ACTIVITIES

Professional Society Activities, with Offices Held

National and International

American Society of Clinical Oncology
Member, 1/2009-present

American Society of Hematology
Member, 1/2009-present

American Association for Cancer Research
Member, 1/2010-present

Association for Patient Oriented Research
Member, 1/2010-present

American Society of Hematology, Washington, DC
Abstract Review Team, 8/2015-present

American Association for Physician Leadership
Member, 2018-present

ASCO Government Relations Committee, Alexandria, VA
Committee Member, 3/2019-6/2021

ASCO Government Relations Committee
Chair Elect, 6/2021-6/2022

ASCO Association Board of Directors
Board Member, 6/2022-present

ASCO Government Relations Committee
Chair, 6/2022-6/2023

Alpha Omega Alpha

University of Florida College of Medicine Admissions Committee Member, Member ACP, AMA

University of Florida College of Medicine Class of 2002 Executive Board Member-Service Chair

Local/State

Steering Committee for MS/PhD in Clinical and Translational Sciences, University of Texas Graduate School of Biomedical Sciences
Member, 1/2010-1/2012

DLBCL Clinical Trial Team, MD Anderson Cancer Center Lymphoma Department
Member, 7/2010-present

Oncology Interest Group
Co-Founder, 7/2010-6/2011

Steering Committee for University of Texas M.D. Anderson Hematology Oncology Fellowship Program
Member, 7/2010-6/2011

New Drug Development Team, MD Anderson Cancer Center Lymphoma Department
Member, 1/2013-present

Lymphoma Informatics Committee
Chair, 4/2013-present

UNIQUE ACTIVITIES

1. US Congressional Candidate, Texas 7th District, 2018 election cycle. Endorsed by the Houston Chronicle, Finished 3rd.
2. Steering Committee Chair, Randomized Phase 3 trial titled ZUMA-23 Axicabtagene ciloleucel compared with standard of care chemotherapy in patients with high risk newly diagnosed large B-cell lymphoma, NCT number pending.
3. Steering Committee Chair, Randomized Phase 3 trial titled: A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (SUNMO), NCT05171647
4. Steering Committee Chair, Randomized Phase 3 trial titled :A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9), NCT05144009
5. Steering Committee Member, Randomized Phase 3 trial titled: YTB323 in comparison with standard chemotherapy in patients with relapsed or refractory large B-cell lymphoma, NCT number pending
6. Steering Committee Member, Randomized Phase 3 trial titled: Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA), NCT03570892

DATE OF LAST CV UPDATE

8/30/2023